Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome. ..more
Target
Tested Compound:
Description:
Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Number: 1 X01 MH077633-01
Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA
Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.
To investigate kinase inhibitory effect of the NF-kappaB inhibitor SID-48409448, we tested the compound in kinase assays which include a panel of 353 kinases kinome.
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Number: 1 X01 MH077633-01
Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA
Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.
To investigate kinase inhibitory effect of the NF-kappaB inhibitor SID-48409448, we tested the compound in kinase assays which include a panel of 353 kinases kinome.
Panel Information
Kinase inhibition selectivity assay for compound SID-48409448
§ Panel component ID.
| Data Table(All) | Show more |
| PID§ | Name | Substance | Panel Targets | Description | ||
|---|---|---|---|---|---|---|
| Active | Inactive | |||||
| 1 | AAK1 Inhibition Activity | 1 | AP2 associated kinase 1 [Homo sapiens] [gi:148277037] | Inhibition Activity against kinase AAK1 is provided | ||
| 2 | ABL1 Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1 is provided | ||
| 3 | ABL1(E255K) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(E255K) is provided | ||
| 4 | ABL1(H396P) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(H396P) is provided | ||
| 5 | ABL1(M351T) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(M351T) is provided | ||
| 6 | ABL1(Q252H) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(Q252H) is provided | ||
| 7 | ABL1(T315I) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(T315I) is provided | ||
| 8 | ABL1(Y253F) Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] [gi:62362414] | Inhibition Activity against kinase ABL1(Y253F) is provided | ||
| 9 | ABL2 Inhibition Activity | 1 | v-abl Abelson murine leukemia viral oncogene homolog 2 isoform a [Homo sapiens] [gi:269847768] | Inhibition Activity against kinase ABL2 is provided | ||
| 10 | ACVR1 Inhibition Activity | 1 | activin A type I receptor precursor [Homo sapiens] [gi:4501895] | Inhibition Activity against kinase ACVR1 is provided | ||
| 11 | ACVR1B Inhibition Activity | 1 | activin A type IB receptor isoform a precursor [Homo sapiens] [gi:4757720] | Inhibition Activity against kinase ACVR1B is provided | ||
| 12 | ACVR2A Inhibition Activity | 1 | activin A receptor, type IIA precursor [Homo sapiens] [gi:4501897] | Inhibition Activity against kinase ACVR2A is provided | ||
| 13 | ACVR2B Inhibition Activity | 1 | activin A type IIB receptor precursor [Homo sapiens] [gi:116734708] | Inhibition Activity against kinase ACVR2B is provided | ||
| 14 | ACVRL1 Inhibition Activity | 1 | activin A receptor type II-like 1 [Homo sapiens] [gi:116734712] | Inhibition Activity against kinase ACVRL1 is provided | ||
| 15 | ADCK3 Inhibition Activity | 1 | chaperone, ABC1 activity of bc1 complex like precursor [Homo sapiens] [gi:34147522] | Inhibition Activity against kinase ADCK3 is provided | ||
| 16 | ADCK4 Inhibition Activity | 1 | aarF domain containing kinase 4 [Homo sapiens] [gi:27363457] | Inhibition Activity against kinase ADCK4 is provided | ||
| 17 | AKT1 Inhibition Activity | 1 | v-akt murine thymoma viral oncogene homolog 1 [Homo sapiens] [gi:62241011] | Inhibition Activity against kinase AKT1 is provided | ||
| 18 | AKT2 Inhibition Activity | 1 | v-akt murine thymoma viral oncogene homolog 2 [Homo sapiens] [gi:4502023] | Inhibition Activity against kinase AKT2 is provided | ||
| 19 | AKT3 Inhibition Activity | 1 | v-akt murine thymoma viral oncogene homolog 3 isoform 1 [Homo sapiens] [gi:4885549] | Inhibition Activity against kinase AKT3 is provided | ||
| 20 | ALK Inhibition Activity | 1 | anaplastic lymphoma kinase Ki-1 [Homo sapiens] [gi:29029632] | Inhibition Activity against kinase ALK is provided | ||
| 21 | AMPK-alpha1 Inhibition Activity | 1 | AMP-activated protein kinase alpha-1 [Homo sapiens] [gi:4115829] | Inhibition Activity against kinase AMPK-alpha1 is provided | ||
| 22 | AMPK-alpha2 Inhibition Activity | 1 | AMP-activated protein kinase alpha 2 catalytic subunit [Homo sapiens] [gi:46877068] | Inhibition Activity against kinase AMPK-alpha2 is provided | ||
| 23 | ANKK1 Inhibition Activity | 1 | ankyrin repeat and kinase domain containing 1 [Homo sapiens] [gi:30425444] | Inhibition Activity against kinase ANKK1 is provided | ||
| 24 | ARK5 Inhibition Activity | 1 | AMPK-related protein kinase 5 [Homo sapiens] [gi:7662170] | Inhibition Activity against kinase ARK5 is provided | ||
| 25 | AURKA Inhibition Activity | 1 | serine/threonine protein kinase 6 [Homo sapiens] [gi:38327562] | Inhibition Activity against kinase AURKA is provided | ||
| 26 | AURKB Inhibition Activity | 1 | Aurora kinase B [Homo sapiens] [gi:127796234] | Inhibition Activity against kinase AURKB is provided | ||
| 27 | AURKC Inhibition Activity | 1 | serine/threonine kinase 13 [Homo sapiens] [gi:3127068] | Inhibition Activity against kinase AURKC is provided | ||
| 28 | AXL Inhibition Activity | 1 | AXL receptor tyrosine kinase isoform 2 [Homo sapiens] [gi:21536468] | Inhibition Activity against kinase AXL is provided | ||
| 29 | BIKE Inhibition Activity | 1 | BMP-2 inducible kinase isoform b [Homo sapiens] [gi:38787904] | Inhibition Activity against kinase BIKE is provided | ||
| 30 | BLK Inhibition Activity | 1 | B lymphoid tyrosine kinase [Homo sapiens] [gi:33469982] | Inhibition Activity against kinase BLK is provided | ||
| 31 | BMPR1A Inhibition Activity | 1 | bone morphogenetic protein receptor, type IA precursor [Homo sapiens] [gi:41349437] | Inhibition Activity against kinase BMPR1A is provided | ||
| 32 | BMPR2 Inhibition Activity | 1 | bone morphogenetic protein receptor type II precursor [Homo sapiens] [gi:15451916] | Inhibition Activity against kinase BMPR2 is provided | ||
| 33 | BMX Inhibition Activity | 1 | BMX non-receptor tyrosine kinase [Homo sapiens] [gi:4502435] | Inhibition Activity against kinase BMX is provided | ||
| 34 | BRAF Inhibition Activity | 1 | v-raf murine sarcoma viral oncogene homolog B1 [Homo sapiens] [gi:33188459] | Inhibition Activity against kinase BRAF is provided | ||
| 35 | BRAF(V600E) Inhibition Activity | 1 | v-raf murine sarcoma viral oncogene homolog B1 [Homo sapiens] [gi:33188459] | Inhibition Activity against kinase BRAF(V600E) is provided | ||
| 36 | BRSK1 Inhibition Activity | 1 | BR serine/threonine kinase 1 [Homo sapiens] [gi:24308326] | Inhibition Activity against kinase BRSK1 is provided | ||
| 37 | BRSK2 Inhibition Activity | 1 | BR serine/threonine kinase 2 [Homo sapiens] [gi:116089335] | Inhibition Activity against kinase BRSK2 is provided | ||
| 38 | BTK Inhibition Activity | 1 | Bruton agammaglobulinemia tyrosine kinase [Homo sapiens] [gi:4557377] | Inhibition Activity against kinase BTK is provided | ||
| 39 | CAMK1 Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase I [Homo sapiens] [gi:4502553] | Inhibition Activity against kinase CAMK1 is provided | ||
| 40 | CAMK1D Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase ID isoform 1 [Homo sapiens] [gi:9966875] | Inhibition Activity against kinase CAMK1D is provided | ||
| 41 | CAMK1G Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase IG [Homo sapiens] [gi:14196445] | Inhibition Activity against kinase CAMK1G is provided | ||
| 42 | CAMK2A Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase IIA isoform 2 [Homo sapiens] [gi:25952118] | Inhibition Activity against kinase CAMK2A is provided | ||
| 43 | CAMK2B Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase IIB isoform 1 [Homo sapiens] [gi:26051204] | Inhibition Activity against kinase CAMK2B is provided | ||
| 44 | CAMK2D Inhibition Activity | 1 | multifunctional calcium/calmodulin-dependent protein kinase II delta2 isoform [Homo sapiens] [gi:4426595] | Inhibition Activity against kinase CAMK2D is provided | ||
| 45 | CAMK2G Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase II gamma isoform 6 [Homo sapiens] [gi:26667211] | Inhibition Activity against kinase CAMK2G is provided | ||
| 46 | CAMK4 Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase IV [Homo sapiens] [gi:4502557] | Inhibition Activity against kinase CAMK4 is provided | ||
| 47 | CAMKK1 Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase 1 alpha isoform a [Homo sapiens] [gi:14150045] | Inhibition Activity against kinase CAMKK1 is provided | ||
| 48 | CAMKK2 Inhibition Activity | 1 | calcium/calmodulin-dependent protein kinase kinase 2 beta isoform 1 [Homo sapiens] [gi:27437015] | Inhibition Activity against kinase CAMKK2 is provided | ||
| 49 | CDC2L1 Inhibition Activity | 1 | cell division cycle 2-like 1 (PITSLRE proteins) isoform 4 [Homo sapiens] [gi:16332362] | Inhibition Activity against kinase CDC2L1 is provided | ||
| 50 | CDC2L2 Inhibition Activity | 1 | cell division cycle 2-like 2 isoform 1 [Homo sapiens] [gi:148763347] | Inhibition Activity against kinase CDC2L2 is provided | ||
| 51 | CDK11 Inhibition Activity | 1 | cell division cycle 2-like 6 (CDK8-like) [Homo sapiens] [gi:30387611] | Inhibition Activity against kinase CDK11 is provided | ||
| 52 | CDK2 Inhibition Activity | 1 | cyclin-dependent kinase 2 isoform 1 [Homo sapiens] [gi:16936528] | Inhibition Activity against kinase CDK2 is provided | ||
| 53 | CDK3 Inhibition Activity | 1 | cyclin-dependent kinase 3 [Homo sapiens] [gi:4557439] | Inhibition Activity against kinase CDK3 is provided | ||
| 54 | CDK5 Inhibition Activity | 1 | cyclin-dependent kinase 5 [Homo sapiens] [gi:4826675] | Inhibition Activity against kinase CDK5 is provided | ||
| 55 | CDK7 Inhibition Activity | 1 | cyclin-dependent kinase 7 [Homo sapiens] [gi:4502743] | Inhibition Activity against kinase CDK7 is provided | ||
| 56 | CDK8 Inhibition Activity | 1 | cyclin-dependent kinase 8 [Homo sapiens] [gi:4502745] | Inhibition Activity against kinase CDK8 is provided | ||
| 57 | CDK9 Inhibition Activity | 1 | cyclin-dependent kinase 9 [Homo sapiens] [gi:4502747] | Inhibition Activity against kinase CDK9 is provided | ||
| 58 | CHEK1 Inhibition Activity | 1 | CHK1 checkpoint homolog [Homo sapiens] [gi:166295192] | Inhibition Activity against kinase CHEK1 is provided | ||
| 59 | CIT Inhibition Activity | 1 | citron [Homo sapiens] [gi:32698688] | Inhibition Activity against kinase CIT is provided | ||
| 60 | CLK1 Inhibition Activity | 1 | clk1; putative [gi:632964] | Inhibition Activity against kinase CLK1 is provided | ||
| 61 | CLK2 Inhibition Activity | 1 | CDC-like kinase 2 [Homo sapiens] [gi:47717134] | Inhibition Activity against kinase CLK2 is provided | ||
| 62 | CLK3 Inhibition Activity | 1 | CDC-like kinase 3 isoform b [Homo sapiens] [gi:153791372] | Inhibition Activity against kinase CLK3 is provided | ||
| 63 | CLK4 Inhibition Activity | 1 | CDC-like kinase 4 [Homo sapiens] [gi:10190706] | Inhibition Activity against kinase CLK4 is provided | ||
| 64 | CSF1R Inhibition Activity | 1 | colony stimulating factor 1 receptor precursor [Homo sapiens] [gi:27262659] | Inhibition Activity against kinase CSF1R is provided | ||
| 65 | CSK Inhibition Activity | 1 | c-src tyrosine kinase [Homo sapiens] [gi:4758078] | Inhibition Activity against kinase CSK is provided | ||
| 66 | CSNK1A1L Inhibition Activity | 1 | casein kinase 1, alpha 1-like [Homo sapiens] [gi:269846834] | Inhibition Activity against kinase CSNK1A1L is provided | ||
| 67 | CSNK1D Inhibition Activity | 1 | casein kinase 1, delta isoform 2 [Homo sapiens] [gi:20544145] | Inhibition Activity against kinase CSNK1D is provided | ||
| 68 | CSNK1E Inhibition Activity | 1 | casein kinase 1 epsilon [Homo sapiens] [gi:4503093] | Inhibition Activity against kinase CSNK1E is provided | ||
| 69 | CSNK1G1 Inhibition Activity | 1 | casein kinase 1, gamma 1 [Homo sapiens] [gi:98986450] | Inhibition Activity against kinase CSNK1G1 is provided | ||
| 70 | CSNK1G2 Inhibition Activity | 1 | casein kinase 1, gamma 2 [Homo sapiens] [gi:153791733] | Inhibition Activity against kinase CSNK1G2 is provided | ||
| 71 | CSNK1G3 Inhibition Activity | 1 | casein kinase 1, gamma 3 isoform 1 [Homo sapiens] [gi:73532778] | Inhibition Activity against kinase CSNK1G3 is provided | ||
| 72 | CSNK2A1 Inhibition Activity | 1 | casein kinase II alpha 1 subunit isoform a [Homo sapiens] [gi:4503095] | Inhibition Activity against kinase CSNK2A1 is provided | ||
| 73 | CSNK2A2 Inhibition Activity | 1 | casein kinase 2, alpha prime polypeptide [Homo sapiens] [gi:4503097] | Inhibition Activity against kinase CSNK2A2 is provided | ||
| 74 | DAPK1 Inhibition Activity | 1 | death-associated protein kinase 1 [Homo sapiens] [gi:89363047] | Inhibition Activity against kinase DAPK1 is provided | ||
| 75 | DAPK2 Inhibition Activity | 1 | death-associated protein kinase 2 [Homo sapiens] [gi:14670383] | Inhibition Activity against kinase DAPK2 is provided | ||
| 76 | DAPK3 Inhibition Activity | 1 | death-associated protein kinase 3 [Homo sapiens] [gi:4557511] | Inhibition Activity against kinase DAPK3 is provided | ||
| 77 | DCAMKL1 Inhibition Activity | 1 | doublecortin and CaM kinase-like 1 [Homo sapiens] [gi:4758128] | Inhibition Activity against kinase DCAMKL1 is provided | ||
| 78 | DCAMKL2 Inhibition Activity | 1 | doublecortin and CaM kinase-like 2 isoform b [Homo sapiens] [gi:306774095] | Inhibition Activity against kinase DCAMKL2 is provided | ||
| 79 | DCAMKL3 Inhibition Activity | 1 | PREDICTED: similar to doublecortin and CaM kinase-like 3 [Homo sapiens] [gi:149589021] | Inhibition Activity against kinase DCAMKL3 is provided | ||
| 80 | DDR1 Inhibition Activity | 1 | discoidin domain receptor family, member 1 isoform b [Homo sapiens] [gi:38327632] | Inhibition Activity against kinase DDR1 is provided | ||
| 81 | DDR2 Inhibition Activity | 1 | protein-tyrosine kinase [Homo sapiens] [gi:433338] | Inhibition Activity against kinase DDR2 is provided | ||
| 82 | DLK Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 12 [Homo sapiens] [gi:301898341] | Inhibition Activity against kinase DLK is provided | ||
| 83 | DMPK Inhibition Activity | 1 | myotonic dystrophy protein kinase isoform 2 [Homo sapiens] [gi:47059024] | Inhibition Activity against kinase DMPK is provided | ||
| 84 | DMPK2 Inhibition Activity | 1 | CDC42 binding protein kinase gamma (DMPK-like) [Homo sapiens] [gi:156766068] | Inhibition Activity against kinase DMPK2 is provided | ||
| 85 | DRAK1 Inhibition Activity | 1 | serine/threonine kinase 17a [Homo sapiens] [gi:109255245] | Inhibition Activity against kinase DRAK1 is provided | ||
| 86 | DRAK2 Inhibition Activity | 1 | serine/threonine kinase 17b [Homo sapiens] [gi:4758194] | Inhibition Activity against kinase DRAK2 is provided | ||
| 87 | DYRK1B Inhibition Activity | 1 | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B isoform a [Homo sapiens] [gi:4758222] | Inhibition Activity against kinase DYRK1B is provided | ||
| 88 | EGFR Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR is provided | ||
| 89 | EGFR(E746-A750del) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(E746-A750del) is provided | ||
| 90 | EGFR(G719C) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(G719C) is provided | ||
| 91 | EGFR(G719S) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(G719S) is provided | ||
| 92 | EGFR(L858R) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(L858R) is provided | ||
| 93 | EGFR(L861Q) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(L861Q) is provided | ||
| 94 | EGFR(S752-I759del) Inhibition Activity | 1 | epidermal growth factor receptor isoform a precursor [Homo sapiens] [gi:29725609] | Inhibition Activity against kinase EGFR(S752-I759del) is provided | ||
| 95 | EPHA1 Inhibition Activity | 1 | ephrin receptor EphA1 [Homo sapiens] [gi:221316650] | Inhibition Activity against kinase EPHA1 is provided | ||
| 96 | EPHA2 Inhibition Activity | 1 | ephrin receptor EphA2 [Homo sapiens] [gi:32967311] | Inhibition Activity against kinase EPHA2 is provided | ||
| 97 | EPHA3 Inhibition Activity | 1 | ephrin receptor EphA3 isoform a precursor [Homo sapiens] [gi:21361241] | Inhibition Activity against kinase EPHA3 is provided | ||
| 98 | EPHA4 Inhibition Activity | 1 | ephrin receptor EphA4 [Homo sapiens] [gi:4758280] | Inhibition Activity against kinase EPHA4 is provided | ||
| 99 | EPHA5 Inhibition Activity | 1 | ephrin receptor EphA5 isoform a [Homo sapiens] [gi:221625401] | Inhibition Activity against kinase EPHA5 is provided | ||
| 100 | EPHA6 Inhibition Activity | 1 | EPH receptor A6 isoform a [Homo sapiens] [gi:145312251] | Inhibition Activity against kinase EPHA6 is provided | ||
| 101 | EPHA7 Inhibition Activity | 1 | ephrin receptor EphA7 [Homo sapiens] [gi:4758282] | Inhibition Activity against kinase EPHA7 is provided | ||
| 102 | EPHA8 Inhibition Activity | 1 | EPH receptor A8 isoform 1 precursor [Homo sapiens] [gi:10140845] | Inhibition Activity against kinase EPHA8 is provided | ||
| 103 | EPHB1 Inhibition Activity | 1 | ephrin receptor EphB1 precursor [Homo sapiens] [gi:4758284] | Inhibition Activity against kinase EPHB1 is provided | ||
| 104 | EPHB2 Inhibition Activity | 1 | ephrin receptor EphB2 isoform 1 precursor [Homo sapiens] [gi:111118978] | Inhibition Activity against kinase EPHB2 is provided | ||
| 105 | EPHB3 Inhibition Activity | 1 | ephrin receptor EphB3 precursor [Homo sapiens] [gi:17975768] | Inhibition Activity against kinase EPHB3 is provided | ||
| 106 | EPHB4 Inhibition Activity | 1 | ephrin receptor EphB4 precursor [Homo sapiens] [gi:32528301] | Inhibition Activity against kinase EPHB4 is provided | ||
| 107 | ERBB2 Inhibition Activity | 1 | erbB-2 isoform b [Homo sapiens] [gi:54792098] | Inhibition Activity against kinase ERBB2 is provided | ||
| 108 | ERBB4 Inhibition Activity | 1 | v-erb-a erythroblastic leukemia viral oncogene homolog 4 isoform JM-a/CVT-2 precursor [Homo sapiens] [gi:110825958] | Inhibition Activity against kinase ERBB4 is provided | ||
| 109 | ERK1 Inhibition Activity | 1 | mitogen-activated protein kinase 3 isoform 1 [Homo sapiens] [gi:91718899] | Inhibition Activity against kinase ERK1 is provided | ||
| 110 | ERK2 Inhibition Activity | 1 | mitogen-activated protein kinase 1 [Homo sapiens] [gi:20986531] | Inhibition Activity against kinase ERK2 is provided | ||
| 111 | ERK3 Inhibition Activity | 1 | mitogen-activated protein kinase 6 [Homo sapiens] [gi:4506091] | Inhibition Activity against kinase ERK3 is provided | ||
| 112 | ERK4 Inhibition Activity | 1 | mitogen-activated protein kinase 4 [Homo sapiens] [gi:89276769] | Inhibition Activity against kinase ERK4 is provided | ||
| 113 | ERK5 Inhibition Activity | 1 | mitogen-activated protein kinase 7 isoform 1 [Homo sapiens] [gi:20986497] | Inhibition Activity against kinase ERK5 is provided | ||
| 114 | ERK8 Inhibition Activity | 1 | mitogen-activated protein kinase 15 [Homo sapiens] [gi:95147356] | Inhibition Activity against kinase ERK8 is provided | ||
| 115 | FER Inhibition Activity | 1 | fer (fps/fes related) tyrosine kinase [Homo sapiens] [gi:119964721] | Inhibition Activity against kinase FER is provided | ||
| 116 | FES Inhibition Activity | 1 | V-FES feline sarcoma viral/V-FPS fujinami avian sarcoma viral oncogene homolog [Homo sapiens] [gi:4503687] | Inhibition Activity against kinase FES is provided | ||
| 117 | FGFR1 Inhibition Activity | 1 | fibroblast growth factor receptor 1 isoform 3 precursor [Homo sapiens] [gi:13186234] | Inhibition Activity against kinase FGFR1 is provided | ||
| 118 | FGFR2 Inhibition Activity | 1 | fibroblast growth factor receptor 2 isoform 2 precursor [Homo sapiens] [gi:221316638] | Inhibition Activity against kinase FGFR2 is provided | ||
| 119 | FGFR3 Inhibition Activity | 1 | fibroblast growth factor receptor 3 isoform 1 precursor [Homo sapiens] [gi:4503711] | Inhibition Activity against kinase FGFR3 is provided | ||
| 120 | FGFR3(G697C) Inhibition Activity | 1 | fibroblast growth factor receptor 3 isoform 1 precursor [Homo sapiens] [gi:4503711] | Inhibition Activity against kinase FGFR3(G697C) is provided | ||
| 121 | FGFR4 Inhibition Activity | 1 | fibroblast growth factor receptor 4 isoform 2 precursor [Homo sapiens] [gi:47524177] | Inhibition Activity against kinase FGFR4 is provided | ||
| 122 | FGR Inhibition Activity | 1 | proto-oncogene tyrosine-protein kinase FGR [Homo sapiens] [gi:4885235] | Inhibition Activity against kinase FGR is provided | ||
| 123 | FLT1 Inhibition Activity | 1 | fms-related tyrosine kinase 1 [Homo sapiens] [gi:156104876] | Inhibition Activity against kinase FLT1 is provided | ||
| 124 | FLT3 Inhibition Activity | 1 | fms-related tyrosine kinase 3 [Homo sapiens] [gi:121114304] | Inhibition Activity against kinase FLT3 is provided | ||
| 125 | FLT3(D835H) Inhibition Activity | 1 | fms-related tyrosine kinase 3 [Homo sapiens] [gi:121114304] | Inhibition Activity against kinase FLT3(D835H) is provided | ||
| 126 | FLT3(D835Y) Inhibition Activity | 1 | fms-related tyrosine kinase 3 [Homo sapiens] [gi:121114304] | Inhibition Activity against kinase FLT3(D835Y) is provided | ||
| 127 | FLT3(ITD) Inhibition Activity | 1 | fms-related tyrosine kinase 3 [Homo sapiens] [gi:121114304] | Inhibition Activity against kinase FLT3(ITD) is provided | ||
| 128 | FLT3(N841I) Inhibition Activity | 1 | fms-related tyrosine kinase 3 [Homo sapiens] [gi:121114304] | Inhibition Activity against kinase FLT3(N841I) is provided | ||
| 129 | FLT4 Inhibition Activity | 1 | unnamed protein product [Homo sapiens] [gi:297050] | Inhibition Activity against kinase FLT4 is provided | ||
| 130 | FRK Inhibition Activity | 1 | fyn-related kinase [Homo sapiens] [gi:4503787] | Inhibition Activity against kinase FRK is provided | ||
| 131 | FYN Inhibition Activity | 1 | protein-tyrosine kinase fyn isoform b [Homo sapiens] [gi:23510362] | Inhibition Activity against kinase FYN is provided | ||
| 132 | GAK Inhibition Activity | 1 | cyclin G associated kinase [Homo sapiens] [gi:157384971] | Inhibition Activity against kinase GAK is provided | ||
| 133 | GSK3A Inhibition Activity | 1 | glycogen synthase kinase 3 alpha [Homo sapiens] [gi:49574532] | Inhibition Activity against kinase GSK3A is provided | ||
| 134 | GSK3B Inhibition Activity | 1 | glycogen synthase kinase 3 beta [Homo sapiens] [gi:21361340] | Inhibition Activity against kinase GSK3B is provided | ||
| 135 | HCK Inhibition Activity | 1 | hemopoietic cell kinase isoform p61HCK [Homo sapiens] [gi:30795229] | Inhibition Activity against kinase HCK is provided | ||
| 136 | IGF1R Inhibition Activity | 1 | insulin-like growth factor 1 receptor precursor [Homo sapiens] [gi:4557665] | Inhibition Activity against kinase IGF1R is provided | ||
| 137 | IKK-epsilon Inhibition Activity | 1 | IKK-related kinase epsilon [Homo sapiens] [gi:7661946] | Inhibition Activity against kinase IKK-epsilon is provided | ||
| 138 | INSR Inhibition Activity | 1 | insulin receptor isoform Long precursor [Homo sapiens] [gi:119395736] | Inhibition Activity against kinase INSR is provided | ||
| 139 | INSRR Inhibition Activity | 1 | insulin receptor-related receptor precursor [Homo sapiens] [gi:31657140] | Inhibition Activity against kinase INSRR is provided | ||
| 140 | IRAK3 Inhibition Activity | 1 | interleukin-1 receptor-associated kinase 3 [Homo sapiens] [gi:216547519] | Inhibition Activity against kinase IRAK3 is provided | ||
| 141 | ITK Inhibition Activity | 1 | IL2-inducible T-cell kinase [Homo sapiens] [gi:15718680] | Inhibition Activity against kinase ITK is provided | ||
| 142 | JNK1 Inhibition Activity | 1 | mitogen-activated protein kinase 8 isoform JNK1 alpha1 [Homo sapiens] [gi:4506095] | Inhibition Activity against kinase JNK1 is provided | ||
| 143 | JNK2 Inhibition Activity | 1 | mitogen-activated protein kinase 9 isoform JNK2 alpha1 [Homo sapiens] [gi:21237739] | Inhibition Activity against kinase JNK2 is provided | ||
| 144 | JNK3 Inhibition Activity | 1 | mitogen-activated protein kinase 10 isoform 1 [Homo sapiens] [gi:4506081] | Inhibition Activity against kinase JNK3 is provided | ||
| 145 | KIT Inhibition Activity | 1 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] [gi:4557695] | Inhibition Activity against kinase KIT is provided | ||
| 146 | KIT(D816V) Inhibition Activity | 1 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] [gi:4557695] | Inhibition Activity against kinase KIT(D816V) is provided | ||
| 147 | KIT(V559D) Inhibition Activity | 1 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] [gi:4557695] | Inhibition Activity against kinase KIT(V559D) is provided | ||
| 148 | LATS1 Inhibition Activity | 1 | LATS homolog 1 [Homo sapiens] [gi:4758666] | Inhibition Activity against kinase LATS1 is provided | ||
| 149 | LATS2 Inhibition Activity | 1 | LATS, large tumor suppressor, homolog 2 [Homo sapiens] [gi:126507091] | Inhibition Activity against kinase LATS2 is provided | ||
| 150 | LCK Inhibition Activity | 1 | lymphocyte-specific protein tyrosine kinase precursor [Homo sapiens] [gi:112789546] | Inhibition Activity against kinase LCK is provided | ||
| 151 | LIMK1 Inhibition Activity | 1 | LIM domain kinase 1 [Homo sapiens] [gi:4505001] | Inhibition Activity against kinase LIMK1 is provided | ||
| 152 | LIMK2 Inhibition Activity | 1 | LIM domain kinase 2 isoform 2a [Homo sapiens] [gi:5031869] | Inhibition Activity against kinase LIMK2 is provided | ||
| 153 | LKB1 Inhibition Activity | 1 | serine/threonine protein kinase 11 [Homo sapiens] [gi:4507271] | Inhibition Activity against kinase LKB1 is provided | ||
| 154 | LOK Inhibition Activity | 1 | protein kinase [Homo sapiens] [gi:4001688] | Inhibition Activity against kinase LOK is provided | ||
| 155 | LTK Inhibition Activity | 1 | leukocyte tyrosine kinase isoform 2 precursor [Homo sapiens] [gi:46249416] | Inhibition Activity against kinase LTK is provided | ||
| 156 | LYN Inhibition Activity | 1 | Yamaguchi sarcoma viral (v-yes-1) oncogene homolog isoform A [Homo sapiens] [gi:4505055] | Inhibition Activity against kinase LYN is provided | ||
| 157 | MAP3K4 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 4 isoform a [Homo sapiens] [gi:55956904] | Inhibition Activity against kinase MAP3K4 is provided | ||
| 158 | MAP3K5 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 5 [Homo sapiens] [gi:5174547] | Inhibition Activity against kinase MAP3K5 is provided | ||
| 159 | MAP4K1 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase kinase 1 isoform 1 [Homo sapiens] [gi:110611908] | Inhibition Activity against kinase MAP4K1 is provided | ||
| 160 | MAP4K3 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase kinase 3 [Homo sapiens] [gi:15451902] | Inhibition Activity against kinase MAP4K3 is provided | ||
| 161 | MAP4K4 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase kinase 4 isoform 2 [Homo sapiens] [gi:22035604] | Inhibition Activity against kinase MAP4K4 is provided | ||
| 162 | MAP4K5 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase kinase 5 [Homo sapiens] [gi:14589909] | Inhibition Activity against kinase MAP4K5 is provided | ||
| 163 | MAPKAPK2 Inhibition Activity | 1 | mitogen-activated protein kinase-activated protein kinase 2 isoform 2 [Homo sapiens] [gi:32481209] | Inhibition Activity against kinase MAPKAPK2 is provided | ||
| 164 | MARK1 Inhibition Activity | 1 | MAP/microtubule affinity-regulating kinase 1 [Homo sapiens] [gi:55665540] | Inhibition Activity against kinase MARK1 is provided | ||
| 165 | MARK2 Inhibition Activity | 1 | MAP/microtubule affinity-regulating kinase 2 isoform a [Homo sapiens] [gi:86990441] | Inhibition Activity against kinase MARK2 is provided | ||
| 166 | MARK3 Inhibition Activity | 1 | MAP/microtubule affinity-regulating kinase 3 isoform c [Homo sapiens] [gi:46852166] | Inhibition Activity against kinase MARK3 is provided | ||
| 167 | MARK4 Inhibition Activity | 1 | MAP/microtubule affinity-regulating kinase 4 [Homo sapiens] [gi:33636756] | Inhibition Activity against kinase MARK4 is provided | ||
| 168 | MEK1 Inhibition Activity | 1 | mitogen-activated protein kinase kinase 1 [Homo sapiens] [gi:5579478] | Inhibition Activity against kinase MEK1 is provided | ||
| 169 | MEK2 Inhibition Activity | 1 | mitogen-activated protein kinase kinase 2 [Homo sapiens] [gi:13489054] | Inhibition Activity against kinase MEK2 is provided | ||
| 170 | MEK3 Inhibition Activity | 1 | mitogen-activated protein kinase kinase 3 isoform A [Homo sapiens] [gi:21618347] | Inhibition Activity against kinase MEK3 is provided | ||
| 171 | MEK4 Inhibition Activity | 1 | mitogen-activated protein kinase kinase 4 [Homo sapiens] [gi:4506889] | Inhibition Activity against kinase MEK4 is provided | ||
| 172 | MEK6 Inhibition Activity | 1 | mitogen-activated protein kinase kinase 6 [Homo sapiens] [gi:14589900] | Inhibition Activity against kinase MEK6 is provided | ||
| 173 | MELK Inhibition Activity | 1 | maternal embryonic leucine zipper kinase [Homo sapiens] [gi:7661974] | Inhibition Activity against kinase MELK is provided | ||
| 174 | MERTK Inhibition Activity | 1 | novel cellular proto-oncogene [gi:505665] | Inhibition Activity against kinase MERTK is provided | ||
| 175 | MET Inhibition Activity | 1 | met proto-oncogene isoform b precursor [Homo sapiens] [gi:42741655] | Inhibition Activity against kinase MET is provided | ||
| 176 | MKNK1 Inhibition Activity | 1 | MAP kinase interacting serine/threonine kinase 1 [Homo sapiens] [gi:55957746] | Inhibition Activity against kinase MKNK1 is provided | ||
| 177 | MKNK2 Inhibition Activity | 1 | map kinase-interacting kinase [Homo sapiens] [gi:6563264] | Inhibition Activity against kinase MKNK2 is provided | ||
| 178 | MLCK Inhibition Activity | 1 | myosin light chain kinase 3 [Homo sapiens] [gi:146219832] | Inhibition Activity against kinase MLCK is provided | ||
| 179 | MLK1 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 9 [Homo sapiens] [gi:52421790] | Inhibition Activity against kinase MLK1 is provided | ||
| 180 | MLK2 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 10 [Homo sapiens] [gi:21735550] | Inhibition Activity against kinase MLK2 is provided | ||
| 181 | MLK3 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 11 [Homo sapiens] [gi:4505195] | Inhibition Activity against kinase MLK3 is provided | ||
| 182 | MRCKA Inhibition Activity | 1 | CDC42-binding protein kinase alpha isoform B [Homo sapiens] [gi:30089962] | Inhibition Activity against kinase MRCKA is provided | ||
| 183 | MRCKB Inhibition Activity | 1 | CDC42-binding protein kinase beta [Homo sapiens] [gi:115527097] | Inhibition Activity against kinase MRCKB is provided | ||
| 184 | MST1 Inhibition Activity | 1 | serine/threonine kinase 4 [Homo sapiens] [gi:5454096] | Inhibition Activity against kinase MST1 is provided | ||
| 185 | MST2 Inhibition Activity | 1 | serine/threonine kinase 3 (STE20 homolog, yeast) [Homo sapiens] [gi:103471999] | Inhibition Activity against kinase MST2 is provided | ||
| 186 | MST3 Inhibition Activity | 1 | serine/threonine kinase 24 isoform a [Homo sapiens] [gi:20070158] | Inhibition Activity against kinase MST3 is provided | ||
| 187 | MST4 Inhibition Activity | 1 | serine/threonine protein kinase MST4 isoform 1 [Homo sapiens] [gi:15011880] | Inhibition Activity against kinase MST4 is provided | ||
| 188 | MUSK Inhibition Activity | 1 | skeletal muscle receptor tyrosine kinase [Homo sapiens] [gi:5031927] | Inhibition Activity against kinase MUSK is provided | ||
| 189 | MYLK Inhibition Activity | 1 | myosin light chain kinase isoform 2 [Homo sapiens] [gi:116008188] | Inhibition Activity against kinase MYLK is provided | ||
| 190 | MYLK2 Inhibition Activity | 1 | skeletal myosin light chain kinase [Homo sapiens] [gi:14993776] | Inhibition Activity against kinase MYLK2 is provided | ||
| 191 | MYO3A Inhibition Activity | 1 | myosin IIIA [Homo sapiens] [gi:145275208] | Inhibition Activity against kinase MYO3A is provided | ||
| 192 | MYO3B Inhibition Activity | 1 | myosin IIIB isoform 2 [Homo sapiens] [gi:284172512] | Inhibition Activity against kinase MYO3B is provided | ||
| 193 | NDR2 Inhibition Activity | 1 | serine/threonine kinase 38 like [Homo sapiens] [gi:24307971] | Inhibition Activity against kinase NDR2 is provided | ||
| 194 | NEK1 Inhibition Activity | 1 | NIMA (never in mitosis gene a)-related kinase 1 [Homo sapiens] [gi:41872673] | Inhibition Activity against kinase NEK1 is provided | ||
| 195 | NEK2 Inhibition Activity | 1 | NIMA (never in mitosis gene a)-related kinase 2 [Homo sapiens] [gi:4505373] | Inhibition Activity against kinase NEK2 is provided | ||
| 196 | NEK5 Inhibition Activity | 1 | NIMA (never in mitosis gene a)-related kinase 5 [Homo sapiens] [gi:83627721] | Inhibition Activity against kinase NEK5 is provided | ||
| 197 | NEK6 Inhibition Activity | 1 | putative serine-threonine protein kinase [Homo sapiens] [gi:19923407] | Inhibition Activity against kinase NEK6 is provided | ||
| 198 | NEK7 Inhibition Activity | 1 | NIMA (never in mitosis gene a)-related kinase 7 [Homo sapiens] [gi:19424132] | Inhibition Activity against kinase NEK7 is provided | ||
| 199 | NEK9 Inhibition Activity | 1 | NIMA related kinase 9 [Homo sapiens] [gi:222136641] | Inhibition Activity against kinase NEK9 is provided | ||
| 200 | NLK Inhibition Activity | 1 | nemo-like kinase [Homo sapiens] [gi:149408126] | Inhibition Activity against kinase NLK is provided | ||
| 201 | p38-alpha Inhibition Activity | 1 | mitogen-activated protein kinase 14 isoform 2 [Homo sapiens] [gi:20986512] | Inhibition Activity against kinase p38-alpha is provided | ||
| 202 | p38-beta Inhibition Activity | 1 | mitogen-activated protein kinase 11 [Homo sapiens] [gi:20128774] | Inhibition Activity against kinase p38-beta is provided | ||
| 203 | p38-gamma Inhibition Activity | 1 | p38gamma MAP Kinase [Homo sapiens] [gi:1772646] | Inhibition Activity against kinase p38-gamma is provided | ||
| 204 | PAK1 Inhibition Activity | 1 | p21-activated kinase 1 isoform 2 [Homo sapiens] [gi:42794769] | Inhibition Activity against kinase PAK1 is provided | ||
| 205 | PAK2 Inhibition Activity | 1 | p21-activated kinase 2 [Homo sapiens] [gi:32483399] | Inhibition Activity against kinase PAK2 is provided | ||
| 206 | PAK3 Inhibition Activity | 1 | p21-activated kinase 3 isoform a [Homo sapiens] [gi:4505601] | Inhibition Activity against kinase PAK3 is provided | ||
| 207 | PAK4 Inhibition Activity | 1 | p21-activated kinase 4 isoform 3 [Homo sapiens] [gi:62422559] | Inhibition Activity against kinase PAK4 is provided | ||
| 208 | PAK6 Inhibition Activity | 1 | p21-activated kinase 6 [Homo sapiens] [gi:9910476] | Inhibition Activity against kinase PAK6 is provided | ||
| 209 | PAK7/PAK5 Inhibition Activity | 1 | p21-activated kinase 7 [Homo sapiens] [gi:24308191] | Inhibition Activity against kinase PAK7/PAK5 is provided | ||
| 210 | PCTK1 Inhibition Activity | 1 | PCTAIRE protein kinase 1 [Homo sapiens] [gi:5453860] | Inhibition Activity against kinase PCTK1 is provided | ||
| 211 | PCTK2 Inhibition Activity | 1 | serine/threonine protein kinase [Homo sapiens] [gi:36617] | Inhibition Activity against kinase PCTK2 is provided | ||
| 212 | PCTK3 Inhibition Activity | 1 | PCTAIRE protein kinase 3 isoform b [Homo sapiens] [gi:47078229] | Inhibition Activity against kinase PCTK3 is provided | ||
| 213 | PDGFRA Inhibition Activity | 1 | platelet-derived growth factor receptor alpha precursor [Homo sapiens] [gi:5453870] | Inhibition Activity against kinase PDGFRA is provided | ||
| 214 | PDGFRB Inhibition Activity | 1 | platelet-derived growth factor receptor beta precursor [Homo sapiens] [gi:4505683] | Inhibition Activity against kinase PDGFRB is provided | ||
| 215 | PDPK1 Inhibition Activity | 1 | 3-phosphoinositide dependent protein kinase-1 isoform 1 [Homo sapiens] [gi:4505695] | Inhibition Activity against kinase PDPK1 is provided | ||
| 216 | PFTK1 Inhibition Activity | 1 | PFTAIRE protein kinase 1 [Homo sapiens] [gi:6912584] | Inhibition Activity against kinase PFTK1 is provided | ||
| 217 | PHKG1 Inhibition Activity | 1 | phosphorylase kinase gamma subunit 1 [Homo sapiens] [gi:5453882] | Inhibition Activity against kinase PHKG1 is provided | ||
| 218 | PHKG2 Inhibition Activity | 1 | phosphorylase kinase, gamma 2 (testis) [Homo sapiens] [gi:4505785] | Inhibition Activity against kinase PHKG2 is provided | ||
| 219 | PIK3CA Inhibition Activity | 1 | phosphoinositide-3-kinase, catalytic, alpha polypeptide [Homo sapiens] [gi:54792082] | Inhibition Activity against kinase PIK3CA is provided | ||
| 220 | PIK3CA(E545K) Inhibition Activity | 1 | phosphoinositide-3-kinase, catalytic, alpha polypeptide [Homo sapiens] [gi:54792082] | Inhibition Activity against kinase PIK3CA(E545K) is provided | ||
| 221 | PIM1 Inhibition Activity | 1 | pim-1 oncogene [Homo sapiens] [gi:4505811] | Inhibition Activity against kinase PIM1 is provided | ||
| 222 | PIM2 Inhibition Activity | 1 | pim-2 oncogene [Homo sapiens] [gi:42821112] | Inhibition Activity against kinase PIM2 is provided | ||
| 223 | PIM3 Inhibition Activity | 1 | pim-3 oncogene [Homo sapiens] [gi:224591416] | Inhibition Activity against kinase PIM3 is provided | ||
| 224 | PIP5K1A Inhibition Activity | 1 | 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha [Homo sapiens] [gi:1743873] | Inhibition Activity against kinase PIP5K1A is provided | ||
| 225 | PIP5K2B Inhibition Activity | 1 | phosphatidylinositol-5-phosphate 4-kinase, type II, beta [Homo sapiens] [gi:4505819] | Inhibition Activity against kinase PIP5K2B is provided | ||
| 226 | PKAC-alpha Inhibition Activity | 1 | cAMP-dependent protein kinase catalytic subunit alpha isoform 1 [Homo sapiens] [gi:4506055] | Inhibition Activity against kinase PKAC-alpha is provided | ||
| 227 | PKAC-beta Inhibition Activity | 1 | cAMP-dependent protein kinase catalytic subunit beta isoform 2 [Homo sapiens] [gi:4506057] | Inhibition Activity against kinase PKAC-beta is provided | ||
| 228 | PKMYT1 Inhibition Activity | 1 | protein kinase Myt1 isoform 2 [Homo sapiens] [gi:33383239] | Inhibition Activity against kinase PKMYT1 is provided | ||
| 229 | PKN1 Inhibition Activity | 1 | protein kinase N1 isoform 1 [Homo sapiens] [gi:47132591] | Inhibition Activity against kinase PKN1 is provided | ||
| 230 | PKN2 Inhibition Activity | 1 | protein kinase N2 [Homo sapiens] [gi:5453974] | Inhibition Activity against kinase PKN2 is provided | ||
| 231 | PLK1 Inhibition Activity | 1 | polo-like kinase [Homo sapiens] [gi:21359873] | Inhibition Activity against kinase PLK1 is provided | ||
| 232 | PLK3 Inhibition Activity | 1 | polo-like kinase 3 [Homo sapiens] [gi:41872374] | Inhibition Activity against kinase PLK3 is provided | ||
| 233 | PLK4 Inhibition Activity | 1 | Sak [Homo sapiens] [gi:16215696] | Inhibition Activity against kinase PLK4 is provided | ||
| 234 | PRKCD Inhibition Activity | 1 | protein kinase C, delta [Homo sapiens] [gi:31377782] | Inhibition Activity against kinase PRKCD is provided | ||
| 235 | PRKCE Inhibition Activity | 1 | protein kinase C, epsilon [Homo sapiens] [gi:4885563] | Inhibition Activity against kinase PRKCE is provided | ||
| 236 | PRKCH Inhibition Activity | 1 | protein kinase C, eta [Homo sapiens] [gi:28557781] | Inhibition Activity against kinase PRKCH is provided | ||
| 237 | PRKCQ Inhibition Activity | 1 | protein kinase C, theta [Homo sapiens] [gi:5453976] | Inhibition Activity against kinase PRKCQ is provided | ||
| 238 | PRKD1 Inhibition Activity | 1 | protein kinase D1 [Homo sapiens] [gi:115529463] | Inhibition Activity against kinase PRKD1 is provided | ||
| 239 | PRKD2 Inhibition Activity | 1 | protein kinase D2 isoform A [Homo sapiens] [gi:19923468] | Inhibition Activity against kinase PRKD2 is provided | ||
| 240 | PRKD3 Inhibition Activity | 1 | protein kinase D3 [Homo sapiens] [gi:5031689] | Inhibition Activity against kinase PRKD3 is provided | ||
| 241 | PRKG1 Inhibition Activity | 1 | protein kinase, cGMP-dependent, type I isoform 2 [Homo sapiens] [gi:10835242] | Inhibition Activity against kinase PRKG1 is provided | ||
| 242 | PRKG2 Inhibition Activity | 1 | protein kinase, cGMP-dependent, type II [Homo sapiens] [gi:5453978] | Inhibition Activity against kinase PRKG2 is provided | ||
| 243 | PRKR Inhibition Activity | 1 | eukaryotic translation initiation factor 2-alpha kinase 2 [Homo sapiens] [gi:4506103] | Inhibition Activity against kinase PRKR is provided | ||
| 244 | PRKX Inhibition Activity | 1 | protein kinase, X-linked [Homo sapiens] [gi:4826948] | Inhibition Activity against kinase PRKX is provided | ||
| 245 | PTK2 Inhibition Activity | 1 | PTK2 protein tyrosine kinase 2 isoform a [Homo sapiens] [gi:24476013] | Inhibition Activity against kinase PTK2 is provided | ||
| 246 | PTK2B Inhibition Activity | 1 | PTK2B protein tyrosine kinase 2 beta isoform b [Homo sapiens] [gi:27886588] | Inhibition Activity against kinase PTK2B is provided | ||
| 247 | PTK6 Inhibition Activity | 1 | PTK6 protein tyrosine kinase 6 [Homo sapiens] [gi:5174647] | Inhibition Activity against kinase PTK6 is provided | ||
| 248 | RAF1 Inhibition Activity | 1 | v-raf-1 murine leukemia viral oncogene homolog 1 [Homo sapiens] [gi:4506401] | Inhibition Activity against kinase RAF1 is provided | ||
| 249 | RET Inhibition Activity | 1 | ret proto-oncogene isoform c [Homo sapiens] [gi:10862701] | Inhibition Activity against kinase RET is provided | ||
| 250 | RET(M918T) Inhibition Activity | 1 | ret proto-oncogene isoform c [Homo sapiens] [gi:10862701] | Inhibition Activity against kinase RET(M918T) is provided | ||
| 251 | RIOK1 Inhibition Activity | 1 | RIO kinase 1 isoform 1 [Homo sapiens] [gi:23510356] | Inhibition Activity against kinase RIOK1 is provided | ||
| 252 | RIOK3 Inhibition Activity | 1 | sudD suppressor of bimD6 homolog [Homo sapiens] [gi:22325377] | Inhibition Activity against kinase RIOK3 is provided | ||
| 253 | RIPK1 Inhibition Activity | 1 | receptor (TNFRSF)-interacting serine-threonine kinase 1 [Homo sapiens] [gi:57242761] | Inhibition Activity against kinase RIPK1 is provided | ||
| 254 | RIPK2 Inhibition Activity | 1 | receptor-interacting serine-threonine kinase 2 [Homo sapiens] [gi:4506537] | Inhibition Activity against kinase RIPK2 is provided | ||
| 255 | ROS1 Inhibition Activity | 1 | proto-oncogene c-ros-1 protein precursor [Homo sapiens] [gi:19924165] | Inhibition Activity against kinase ROS1 is provided | ||
| 256 | SgK085 Inhibition Activity | 1 | myosin light chain kinase family, member 4 [Homo sapiens] [gi:167466233] | Inhibition Activity against kinase SgK085 is provided | ||
| 257 | SLK Inhibition Activity | 1 | serine/threonine kinase 2 [Homo sapiens] [gi:41281453] | Inhibition Activity against kinase SLK is provided | ||
| 258 | SNARK Inhibition Activity | 1 | NUAK family, SNF1-like kinase, 2 [Homo sapiens] [gi:13569922] | Inhibition Activity against kinase SNARK is provided | ||
| 259 | SNF1LK Inhibition Activity | 1 | SNF1-like kinase [Homo sapiens] [gi:116256471] | Inhibition Activity against kinase SNF1LK is provided | ||
| 260 | SNF1LK2 Inhibition Activity | 1 | SNF1-like kinase 2 [Homo sapiens] [gi:38569460] | Inhibition Activity against kinase SNF1LK2 is provided | ||
| 261 | SRC Inhibition Activity | 1 | proto-oncogene tyrosine-protein kinase SRC [Homo sapiens] [gi:4885609] | Inhibition Activity against kinase SRC is provided | ||
| 262 | SRMS Inhibition Activity | 1 | src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites [Homo sapiens] [gi:18250298] | Inhibition Activity against kinase SRMS is provided | ||
| 263 | SRPK1 Inhibition Activity | 1 | SFRS protein kinase 1 [Homo sapiens] [gi:47419936] | Inhibition Activity against kinase SRPK1 is provided | ||
| 264 | SRPK2 Inhibition Activity | 1 | serine kinase SRPK2 [Homo sapiens] [gi:1857944] | Inhibition Activity against kinase SRPK2 is provided | ||
| 265 | STK16 Inhibition Activity | 1 | PKL12 protein [Homo sapiens] [gi:3367705] | Inhibition Activity against kinase STK16 is provided | ||
| 266 | STK33 Inhibition Activity | 1 | serine/threonine kinase 33 [Homo sapiens] [gi:23943882] | Inhibition Activity against kinase STK33 is provided | ||
| 267 | STK36 Inhibition Activity | 1 | serine/threonine kinase 36 [Homo sapiens] [gi:217330634] | Inhibition Activity against kinase STK36 is provided | ||
| 268 | SYK Inhibition Activity | 1 | spleen tyrosine kinase [Homo sapiens] [gi:21361553] | Inhibition Activity against kinase SYK is provided | ||
| 269 | TEC Inhibition Activity | 1 | tec protein tyrosine kinase [Homo sapiens] [gi:130977759] | Inhibition Activity against kinase TEC is provided | ||
| 270 | TESK1 Inhibition Activity | 1 | testis-specific protein kinase 1 [Homo sapiens] [gi:66932999] | Inhibition Activity against kinase TESK1 is provided | ||
| 271 | TGFBR1 Inhibition Activity | 1 | transforming growth factor, beta receptor I isoform 1 precursor [Homo sapiens] [gi:4759226] | Inhibition Activity against kinase TGFBR1 is provided | ||
| 272 | TGFBR2 Inhibition Activity | 1 | transforming growth factor, beta receptor II isoform B precursor [Homo sapiens] [gi:67782324] | Inhibition Activity against kinase TGFBR2 is provided | ||
| 273 | TIE1 Inhibition Activity | 1 | tyrosine kinase with immunoglobulin-like and EGF-like domains 1 [Homo sapiens] [gi:4885631] | Inhibition Activity against kinase TIE1 is provided | ||
| 274 | TIE2 Inhibition Activity | 1 | TEK tyrosine kinase, endothelial precursor [Homo sapiens] [gi:88758596] | Inhibition Activity against kinase TIE2 is provided | ||
| 275 | TLK1 Inhibition Activity | 1 | tousled-like kinase 1 [Homo sapiens] [gi:33636698] | Inhibition Activity against kinase TLK1 is provided | ||
| 276 | TLK2 Inhibition Activity | 1 | tousled-like kinase 2 [Homo sapiens] [gi:6063019] | Inhibition Activity against kinase TLK2 is provided | ||
| 277 | TNIK Inhibition Activity | 1 | TRAF2 and NCK interacting kinase [Homo sapiens] [gi:55741807] | Inhibition Activity against kinase TNIK is provided | ||
| 278 | TNK1 Inhibition Activity | 1 | TNK1 protein [Homo sapiens] [gi:23273502] | Inhibition Activity against kinase TNK1 is provided | ||
| 279 | TNK2 Inhibition Activity | 1 | tyrosine kinase, non-receptor, 2 isoform 2 [Homo sapiens] [gi:58331191] | Inhibition Activity against kinase TNK2 is provided | ||
| 280 | TNNI3K Inhibition Activity | 1 | TNNI3 interacting kinase isoform b [Homo sapiens] [gi:7705748] | Inhibition Activity against kinase TNNI3K is provided | ||
| 281 | TRKA Inhibition Activity | 1 | neurotrophic tyrosine kinase, receptor, type 1 isoform 1 [Homo sapiens] [gi:59889558] | Inhibition Activity against kinase TRKA is provided | ||
| 282 | TRKB Inhibition Activity | 1 | neurotrophic tyrosine kinase, receptor, type 2 isoform a precursor [Homo sapiens] [gi:21361306] | Inhibition Activity against kinase TRKB is provided | ||
| 283 | TRKC Inhibition Activity | 1 | TrkC [gi:442390] | Inhibition Activity against kinase TRKC is provided | ||
| 284 | TSSK1 Inhibition Activity | 1 | testis-specific serine kinase 1 [Homo sapiens] [gi:14042947] | Inhibition Activity against kinase TSSK1 is provided | ||
| 285 | TTK Inhibition Activity | 1 | TTK protein kinase [Homo sapiens] [gi:23308722] | Inhibition Activity against kinase TTK is provided | ||
| 286 | TXK Inhibition Activity | 1 | TXK tyrosine kinase [Homo sapiens] [gi:148596974] | Inhibition Activity against kinase TXK is provided | ||
| 287 | TYRO3 Inhibition Activity | 1 | TYRO3 protein tyrosine kinase [Homo sapiens] [gi:27597078] | Inhibition Activity against kinase TYRO3 is provided | ||
| 288 | VEGFR2 Inhibition Activity | 1 | kinase insert domain receptor (a type III receptor tyrosine kinase) [Homo sapiens] [gi:11321597] | Inhibition Activity against kinase VEGFR2 is provided | ||
| 289 | WEE1 Inhibition Activity | 1 | wee1 tyrosine kinase [Homo sapiens] [gi:4507917] | Inhibition Activity against kinase WEE1 is provided | ||
| 290 | YANK2 Inhibition Activity | 1 | serine/threonine kinase 32B [Homo sapiens] [gi:8923754] | Inhibition Activity against kinase YANK2 is provided | ||
| 291 | YANK3 Inhibition Activity | 1 | serine/threonine kinase 32C [Homo sapiens] [gi:32455269] | Inhibition Activity against kinase YANK3 is provided | ||
| 292 | YES Inhibition Activity | 1 | viral oncogene yes-1 homolog 1 [Homo sapiens] [gi:4885661] | Inhibition Activity against kinase YES is provided | ||
| 293 | YSK1 Inhibition Activity | 1 | serine/threonine kinase 25 [Homo sapiens] [gi:21361358] | Inhibition Activity against kinase YSK1 is provided | ||
| 294 | ZAK Inhibition Activity | 1 | MLK-related kinase isoform 2 [Homo sapiens] [gi:19526767] | Inhibition Activity against kinase ZAK is provided | ||
| 295 | ZAP70 Inhibition Activity | 1 | zeta-chain associated protein kinase 70kDa isoform 2 [Homo sapiens] [gi:46488944] | Inhibition Activity against kinase ZAP70 is provided | ||
| 296 | ABL1(F317I) Inhibition Activity | 1 | c-abl oncogene 1, receptor tyrosine kinase [gi:62362414] | Inhibition Activity against kinase ABL1(F317I) is provided | ||
| 297 | ABL1(F317L) Inhibition Activity | 1 | c-abl oncogene 1, receptor tyrosine kinase [gi:62362414] | Inhibition Activity against kinase ABL1(F317L) is provided | ||
| 298 | BMPR1B Inhibition Activity | 1 | bone morphogenetic protein receptor, type IB [gi:4502431] | Inhibition Activity against kinase BMPR1B is provided | ||
| 299 | CDKL2 Inhibition Activity | 1 | cyclin-dependent kinase-like 2 (CDC2-related kinase) [gi:4505569] | Inhibition Activity against kinase CDKL2 is provided | ||
| 300 | CHEK2 Inhibition Activity | 1 | CHK2 checkpoint homolog (S. pombe) [gi:54112407] | Inhibition Activity against kinase CHEK2 is provided | ||
| 301 | EGFR(L747-E749del, A750P) Inhibition Activity | 1 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) [gi:29725609] | Inhibition Activity against kinase EGFR(L747-E749del, A750P) is provided | ||
| 302 | EGFR(L747-S752del, P753S) Inhibition Activity | 1 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) [gi:29725609] | Inhibition Activity against kinase EGFR(L747-S752del, P753S) is provided | ||
| 303 | EGFR(L747-T751del,Sins) Inhibition Activity | 1 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) [gi:29725609] | Inhibition Activity against kinase EGFR(L747-T751del,Sins) is provided | ||
| 304 | FLT3(K663Q) Inhibition Activity | 1 | fms-related tyrosine kinase 3 [gi:121114304] | Inhibition Activity against kinase FLT3(K663Q) is provided | ||
| 305 | GCN2(Kin.Dom.2,S808G) Inhibition Activity | 1 | eukaryotic translation initiation factor 2 alpha kinase 4 [gi:65287717] | Inhibition Activity against kinase GCN2(Kin.Dom.2,S808G) is provided | ||
| 306 | HIPK1 Inhibition Activity | 1 | homeodomain interacting protein kinase 1 [gi:38201638] | Inhibition Activity against kinase HIPK1 is provided | ||
| 307 | IKK-alpha Inhibition Activity | 1 | conserved helix-loop-helix ubiquitous kinase [gi:62241001] | Inhibition Activity against kinase IKK-alpha is provided | ||
| 308 | IKK-beta Inhibition Activity | 1 | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta [gi:41352712] | Inhibition Activity against kinase IKK-beta is provided | ||
| 309 | JAK1(Kin.Dom.1) Inhibition Activity | 1 | Janus kinase 1 [gi:102469034] | Inhibition Activity against kinase JAK1(Kin.Dom.1) is provided | ||
| 310 | JAK1(Kin.Dom.2) Inhibition Activity | 1 | Janus kinase 1 [gi:102469034] | Inhibition Activity against kinase JAK1(Kin.Dom.2) is provided | ||
| 311 | JAK2(Kin.Dom.2) Inhibition Activity | 1 | Janus kinase 2 [gi:4826776] | Inhibition Activity against kinase JAK2(Kin.Dom.2) is provided | ||
| 312 | JAK3(Kin.Dom.2) Inhibition Activity | 1 | Janus kinase 3 [gi:47157315] | Inhibition Activity against kinase JAK3(Kin.Dom.2) is provided | ||
| 313 | KIT(V559D,T670I) Inhibition Activity | 1 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [gi:4557695] | Inhibition Activity against kinase KIT(V559D,T670I) is provided | ||
| 314 | KIT(V559D,V654A) Inhibition Activity | 1 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [gi:4557695] | Inhibition Activity against kinase KIT(V559D,V654A) is provided | ||
| 315 | MAP3K3 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 3 [gi:42794765] | Inhibition Activity against kinase MAP3K3 is provided | ||
| 316 | MAP4K2 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase kinase 2 [gi:22035600] | Inhibition Activity against kinase MAP4K2 is provided | ||
| 317 | MAPKAPK5 Inhibition Activity | 1 | mitogen-activated protein kinase-activated protein kinase 5 [gi:21237765] | Inhibition Activity against kinase MAPKAPK5 is provided | ||
| 318 | MINK Inhibition Activity | 1 | misshapen-like kinase 1 (zebrafish) [gi:68161546] | Inhibition Activity against kinase MINK is provided | ||
| 319 | MST1R Inhibition Activity | 1 | macrophage stimulating 1 receptor (c-met-related tyrosine kinase) [gi:153946393] | Inhibition Activity against kinase MST1R is provided | ||
| 320 | p38-delta Inhibition Activity | 1 | mitogen-activated protein kinase 13 [gi:4506085] | Inhibition Activity against kinase p38-delta is provided | ||
| 321 | PFTAIRE2 Inhibition Activity | 1 | PFTAIRE protein kinase 2 [gi:21040235] | Inhibition Activity against kinase PFTAIRE2 is provided | ||
| 322 | PIK3C2B Inhibition Activity | 1 | phosphoinositide-3-kinase, class 2, beta polypeptide [gi:194097347] | Inhibition Activity against kinase PIK3C2B is provided | ||
| 323 | PIK3CB Inhibition Activity | 1 | phosphoinositide-3-kinase, catalytic, beta polypeptide [gi:5453894] | Inhibition Activity against kinase PIK3CB is provided | ||
| 324 | PIK3CD Inhibition Activity | 1 | phosphoinositide-3-kinase, catalytic, delta polypeptide [gi:156564405] | Inhibition Activity against kinase PIK3CD is provided | ||
| 325 | PIK3CG Inhibition Activity | 1 | phosphoinositide-3-kinase, catalytic, gamma polypeptide [gi:21237725] | Inhibition Activity against kinase PIK3CG is provided | ||
| 326 | RET(V804L) Inhibition Activity | 1 | ret proto-oncogene [gi:10862701] | Inhibition Activity against kinase RET(V804L) is provided | ||
| 327 | RET(V804M) Inhibition Activity | 1 | ret proto-oncogene [gi:10862701] | Inhibition Activity against kinase RET(V804M) is provided | ||
| 328 | RIOK2 Inhibition Activity | 1 | RIO kinase 2 (yeast) [gi:229331971] | Inhibition Activity against kinase RIOK2 is provided | ||
| 329 | RIPK4 Inhibition Activity | 1 | receptor-interacting serine-threonine kinase 4 [gi:41327754] | Inhibition Activity against kinase RIPK4 is provided | ||
| 330 | ROCK2 Inhibition Activity | 1 | Rho-associated, coiled-coil containing protein kinase 2 [gi:41872583] | Inhibition Activity against kinase ROCK2 is provided | ||
| 331 | RPS6KA1(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 1 [gi:55743134] | Inhibition Activity against kinase RPS6KA1(Kin.Dom.1) is provided | ||
| 332 | RPS6KA1(Kin.Dom.2) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 1 [gi:55743134] | Inhibition Activity against kinase RPS6KA1(Kin.Dom.2) is provided | ||
| 333 | RPS6KA2(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 2 [gi:55743136] | Inhibition Activity against kinase RPS6KA2(Kin.Dom.1) is provided | ||
| 334 | RPS6KA2(Kin.Dom.2) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 2 [gi:55743136] | Inhibition Activity against kinase RPS6KA2(Kin.Dom.2) is provided | ||
| 335 | RPS6KA3(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 3 [gi:4759050] | Inhibition Activity against kinase RPS6KA3(Kin.Dom.1) is provided | ||
| 336 | RPS6KA4(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 4 [gi:55743138] | Inhibition Activity against kinase RPS6KA4(Kin.Dom.1) is provided | ||
| 337 | RPS6KA4(Kin.Dom.2) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 4 [gi:55743138] | Inhibition Activity against kinase RPS6KA4(Kin.Dom.2) is provided | ||
| 338 | RPS6KA5(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 5 [gi:32528295] | Inhibition Activity against kinase RPS6KA5(Kin.Dom.1) is provided | ||
| 339 | RPS6KA5(Kin.Dom.2) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 5 [gi:32528295] | Inhibition Activity against kinase RPS6KA5(Kin.Dom.2) is provided | ||
| 340 | RPS6KA6(Kin.Dom.1) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 6 [gi:7657526] | Inhibition Activity against kinase RPS6KA6(Kin.Dom.1) is provided | ||
| 341 | RPS6KA6(Kin.Dom.2) Inhibition Activity | 1 | ribosomal protein S6 kinase, 90kDa, polypeptide 6 [gi:7657526] | Inhibition Activity against kinase RPS6KA6(Kin.Dom.2) is provided | ||
| 342 | SgK110 Inhibition Activity | 1 | similar to Putative uncharacterized serine/threonine-protein kinase SgK110 [gi:161783904] | Inhibition Activity against kinase SgK110 is provided | ||
| 343 | SRPK3 Inhibition Activity | 1 | SFRS protein kinase 3 [gi:63025196] | Inhibition Activity against kinase SRPK3 is provided | ||
| 344 | STK35 Inhibition Activity | 1 | serine/threonine kinase 35 [gi:260099625] | Inhibition Activity against kinase STK35 is provided | ||
| 345 | TAK1 Inhibition Activity | 1 | mitogen-activated protein kinase kinase kinase 7 [gi:21735562] | Inhibition Activity against kinase TAK1 is provided | ||
| 346 | TAOK1 Inhibition Activity | 1 | TAO kinase 1 [gi:45439370] | Inhibition Activity against kinase TAOK1 is provided | ||
| 347 | TAOK3 Inhibition Activity | 1 | TAO kinase 3 [gi:148746218] | Inhibition Activity against kinase TAOK3 is provided | ||
| 348 | TYK2(Kin.Dom.1) Inhibition Activity | 1 | tyrosine kinase 2 [gi:187608615] | Inhibition Activity against kinase TYK2(Kin.Dom.1) is provided | ||
| 349 | TYK2(Kin.Dom.2) Inhibition Activity | 1 | tyrosine kinase 2 [gi:187608615] | Inhibition Activity against kinase TYK2(Kin.Dom.2) is provided | ||
| 350 | ULK1 Inhibition Activity | 1 | unc-51-like kinase 1 (C. elegans) [gi:4507831] | Inhibition Activity against kinase ULK1 is provided | ||
| 351 | ULK2 Inhibition Activity | 1 | unc-51-like kinase 2 (C. elegans) [gi:217330557] | Inhibition Activity against kinase ULK2 is provided | ||
| 352 | ULK3 Inhibition Activity | 1 | unc-51-like kinase 3 (C. elegans) [gi:150456432] | Inhibition Activity against kinase ULK3 is provided | ||
| 353 | WEE2 Inhibition Activity | 1 | WEE1 homolog 2 (S. pombe) [gi:254763343] | Inhibition Activity against kinase WEE2 is provided | ||
§ Panel component ID.
Protocol
Kinase screening was done by Ambit Biosciences (San Diego, CA) using a standard protocol, adapted from Karaman, 2008, http://www.nature.com/nbt/journal/v26/n1/abs/nbt1358.html
Briefly,
1. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 strain. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. In general, full-length constructs were used for small, single domain kinases, and catalytic domain constructs for large multidomain kinases.
2. For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays.
3. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding.
4. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1X binding buffer (20% SeaBlock, 0.17X PBS, 0.05% Tween 20, 6 mM DTT).
5. Test compounds were prepared as 40X stocks in 100% DMSO and directly diluted into the assay. All reactions were performed in polypropylene 384-well plates in a final volume of 0.04 ml. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1X PBS, 0.05 % Tween 20). The beads were then re-suspended in elution buffer (1X PBS, 0.05 % Tween 20, 0.5 um non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. Each kinase was tested individually against compound CID-2858522 at final concentration of 10 uM.
6. The kinase concentration in the eluates was measured by qPCR.
7. Data is reported as %Ctrl, or Percent of Control (POC) where lower numbers indicate stronger hits. Any kinase showing 30% activity by the compound is considered as positive candidate for follow up studies.
Briefly,
1. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 strain. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. In general, full-length constructs were used for small, single domain kinases, and catalytic domain constructs for large multidomain kinases.
2. For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays.
3. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding.
4. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1X binding buffer (20% SeaBlock, 0.17X PBS, 0.05% Tween 20, 6 mM DTT).
5. Test compounds were prepared as 40X stocks in 100% DMSO and directly diluted into the assay. All reactions were performed in polypropylene 384-well plates in a final volume of 0.04 ml. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1X PBS, 0.05 % Tween 20). The beads were then re-suspended in elution buffer (1X PBS, 0.05 % Tween 20, 0.5 um non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. Each kinase was tested individually against compound CID-2858522 at final concentration of 10 uM.
6. The kinase concentration in the eluates was measured by qPCR.
7. Data is reported as %Ctrl, or Percent of Control (POC) where lower numbers indicate stronger hits. Any kinase showing 30% activity by the compound is considered as positive candidate for follow up studies.
Comment
Compound CID-2858522 at 10 uM inhibits TLK1 (30% POC) but not significantly inhibit other kinases that are involved in known NF-kappaB pathways.
Result Definitions
| Show more |
| TID | Name | Description | PID§ | Panel Targets | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||||
| 1 | Outcome(ABL1(T315I)) | 7 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] |  | Outcome | |||
| 2 | %Inhibition(ABL1(T315I)) (10μM**) | 7 | | Float | % | |||
| 3 | Outcome(ALK) | 20 | anaplastic lymphoma kinase Ki-1 [Homo sapiens] | | Outcome | |||
| 4 | %Inhibition(ALK) (10μM**) | 20 | | Float | % | |||
| 5 | Outcome(AURKA) | 25 | serine/threonine protein kinase 6 [Homo sapiens] | | Outcome | |||
| 6 | %Inhibition(AURKA) (10μM**) | 25 | | Float | % | |||
| 7 | Outcome(AURKB) | 26 | Aurora kinase B [Homo sapiens] | | Outcome | |||
| 8 | %Inhibition(AURKB) (10μM**) | 26 | | Float | % | |||
| 9 | Outcome(AURKC) | 27 | serine/threonine kinase 13 [Homo sapiens] | | Outcome | |||
| 10 | %Inhibition(AURKC) (10μM**) | 27 | | Float | % | |||
| 11 | Outcome(AXL) | 28 | AXL receptor tyrosine kinase isoform 2 [Homo sapiens] | | Outcome | |||
| 12 | %Inhibition(AXL) (10μM**) | 28 | | Float | % | |||
| 13 | Outcome(BMPR2) | 32 | bone morphogenetic protein receptor type II precursor [Homo sapiens] | | Outcome | |||
| 14 | %Inhibition(BMPR2) (10μM**) | 32 | | Float | % | |||
| 15 | Outcome(CDC2L1) | 49 | cell division cycle 2-like 1 (PITSLRE proteins) isoform 4 [Homo sapiens] | | Outcome | |||
| 16 | %Inhibition(CDC2L1) (10μM**) | 49 | | Float | % | |||
| 17 | Outcome(CDC2L2) | 50 | cell division cycle 2-like 2 isoform 1 [Homo sapiens] | | Outcome | |||
| 18 | %Inhibition(CDC2L2) (10μM**) | 50 | | Float | % | |||
| 19 | Outcome(CDK11) | 51 | cell division cycle 2-like 6 (CDK8-like) [Homo sapiens] | | Outcome | |||
| 20 | %Inhibition(CDK11) (10μM**) | 51 | | Float | % | |||
| 21 | Outcome(CDK7) | 55 | cyclin-dependent kinase 7 [Homo sapiens] | | Outcome | |||
| 22 | %Inhibition(CDK7) (10μM**) | 55 | | Float | % | |||
| 23 | Outcome(CDK8) | 56 | cyclin-dependent kinase 8 [Homo sapiens] | | Outcome | |||
| 24 | %Inhibition(CDK8) (10μM**) | 56 | | Float | % | |||
| 25 | Outcome(CDK9) | 57 | cyclin-dependent kinase 9 [Homo sapiens] | | Outcome | |||
| 26 | %Inhibition(CDK9) (10μM**) | 57 | | Float | % | |||
| 27 | Outcome(CLK1) | 60 | clk1; putative | | Outcome | |||
| 28 | %Inhibition(CLK1) (10μM**) | 60 | | Float | % | |||
| 29 | Outcome(CLK4) | 63 | CDC-like kinase 4 [Homo sapiens] | | Outcome | |||
| 30 | %Inhibition(CLK4) (10μM**) | 63 | | Float | % | |||
| 31 | Outcome(CSF1R) | 64 | colony stimulating factor 1 receptor precursor [Homo sapiens] | | Outcome | |||
| 32 | %Inhibition(CSF1R) (10μM**) | 64 | | Float | % | |||
| 33 | Outcome(DDR1) | 80 | discoidin domain receptor family, member 1 isoform b [Homo sapiens] | | Outcome | |||
| 34 | %Inhibition(DDR1) (10μM**) | 80 | | Float | % | |||
| 35 | Outcome(DDR2) | 81 | protein-tyrosine kinase [Homo sapiens] | | Outcome | |||
| 36 | %Inhibition(DDR2) (10μM**) | 81 | | Float | % | |||
| 37 | Outcome(EGFR(G719C)) | 90 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 38 | %Inhibition(EGFR(G719C)) (10μM**) | 90 | | Float | % | |||
| 39 | Outcome(EPHA3) | 97 | ephrin receptor EphA3 isoform a precursor [Homo sapiens] | | Outcome | |||
| 40 | %Inhibition(EPHA3) (10μM**) | 97 | | Float | % | |||
| 41 | Outcome(EPHA6) | 100 | EPH receptor A6 isoform a [Homo sapiens] | | Outcome | |||
| 42 | %Inhibition(EPHA6) (10μM**) | 100 | | Float | % | |||
| 43 | Outcome(EPHA7) | 101 | ephrin receptor EphA7 [Homo sapiens] | | Outcome | |||
| 44 | %Inhibition(EPHA7) (10μM**) | 101 | | Float | % | |||
| 45 | Outcome(EPHB3) | 105 | ephrin receptor EphB3 precursor [Homo sapiens] | | Outcome | |||
| 46 | %Inhibition(EPHB3) (10μM**) | 105 | | Float | % | |||
| 47 | Outcome(EPHB4) | 106 | ephrin receptor EphB4 precursor [Homo sapiens] | | Outcome | |||
| 48 | %Inhibition(EPHB4) (10μM**) | 106 | | Float | % | |||
| 49 | Outcome(ERK8) | 114 | mitogen-activated protein kinase 15 [Homo sapiens] | | Outcome | |||
| 50 | %Inhibition(ERK8) (10μM**) | 114 | | Float | % | |||
| 51 | Outcome(FLT1) | 123 | fms-related tyrosine kinase 1 [Homo sapiens] | | Outcome | |||
| 52 | %Inhibition(FLT1) (10μM**) | 123 | | Float | % | |||
| 53 | Outcome(FLT3) | 124 | fms-related tyrosine kinase 3 [Homo sapiens] | | Outcome | |||
| 54 | %Inhibition(FLT3) (10μM**) | 124 | | Float | % | |||
| 55 | Outcome(FLT3(D835H)) | 125 | fms-related tyrosine kinase 3 [Homo sapiens] | | Outcome | |||
| 56 | %Inhibition(FLT3(D835H)) (10μM**) | 125 | | Float | % | |||
| 57 | Outcome(FLT3(D835Y)) | 126 | fms-related tyrosine kinase 3 [Homo sapiens] | | Outcome | |||
| 58 | %Inhibition(FLT3(D835Y)) (10μM**) | 126 | | Float | % | |||
| 59 | Outcome(FLT3(ITD)) | 127 | fms-related tyrosine kinase 3 [Homo sapiens] | | Outcome | |||
| 60 | %Inhibition(FLT3(ITD)) (10μM**) | 127 | | Float | % | |||
| 61 | Outcome(FLT3(N841I)) | 128 | fms-related tyrosine kinase 3 [Homo sapiens] | | Outcome | |||
| 62 | %Inhibition(FLT3(N841I)) (10μM**) | 128 | | Float | % | |||
| 63 | Outcome(FLT4) | 129 | unnamed protein product [Homo sapiens] | | Outcome | |||
| 64 | %Inhibition(FLT4) (10μM**) | 129 | | Float | % | |||
| 65 | Outcome(FRK) | 130 | fyn-related kinase [Homo sapiens] | | Outcome | |||
| 66 | %Inhibition(FRK) (10μM**) | 130 | | Float | % | |||
| 67 | Outcome(INSRR) | 139 | insulin receptor-related receptor precursor [Homo sapiens] | | Outcome | |||
| 68 | %Inhibition(INSRR) (10μM**) | 139 | | Float | % | |||
| 69 | Outcome(JNK2) | 143 | mitogen-activated protein kinase 9 isoform JNK2 alpha1 [Homo sapiens] | | Outcome | |||
| 70 | %Inhibition(JNK2) (10μM**) | 143 | | Float | % | |||
| 71 | Outcome(KIT) | 145 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 72 | %Inhibition(KIT) (10μM**) | 145 | | Float | % | |||
| 73 | Outcome(KIT(D816V)) | 146 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 74 | %Inhibition(KIT(D816V)) (10μM**) | 146 | | Float | % | |||
| 75 | Outcome(KIT(V559D)) | 147 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 76 | %Inhibition(KIT(V559D)) (10μM**) | 147 | | Float | % | |||
| 77 | Outcome(LATS2) | 149 | LATS, large tumor suppressor, homolog 2 [Homo sapiens] | | Outcome | |||
| 78 | %Inhibition(LATS2) (10μM**) | 149 | | Float | % | |||
| 79 | Outcome(LIMK2) | 152 | LIM domain kinase 2 isoform 2a [Homo sapiens] | | Outcome | |||
| 80 | %Inhibition(LIMK2) (10μM**) | 152 | | Float | % | |||
| 81 | Outcome(LOK) | 154 | protein kinase [Homo sapiens] | | Outcome | |||
| 82 | %Inhibition(LOK) (10μM**) | 154 | | Float | % | |||
| 83 | Outcome(LTK) | 155 | leukocyte tyrosine kinase isoform 2 precursor [Homo sapiens] | | Outcome | |||
| 84 | %Inhibition(LTK) (10μM**) | 155 | | Float | % | |||
| 85 | Outcome(MAP4K1) | 159 | mitogen-activated protein kinase kinase kinase kinase 1 isoform 1 [Homo sapiens] | | Outcome | |||
| 86 | %Inhibition(MAP4K1) (10μM**) | 159 | | Float | % | |||
| 87 | Outcome(MAP4K3) | 160 | mitogen-activated protein kinase kinase kinase kinase 3 [Homo sapiens] | | Outcome | |||
| 88 | %Inhibition(MAP4K3) (10μM**) | 160 | | Float | % | |||
| 89 | Outcome(MAP4K5) | 162 | mitogen-activated protein kinase kinase kinase kinase 5 [Homo sapiens] | | Outcome | |||
| 90 | %Inhibition(MAP4K5) (10μM**) | 162 | | Float | % | |||
| 91 | Outcome(MERTK) | 174 | novel cellular proto-oncogene | | Outcome | |||
| 92 | %Inhibition(MERTK) (10μM**) | 174 | | Float | % | |||
| 93 | Outcome(MET) | 175 | met proto-oncogene isoform b precursor [Homo sapiens] | | Outcome | |||
| 94 | %Inhibition(MET) (10μM**) | 175 | | Float | % | |||
| 95 | Outcome(MKNK1) | 176 | MAP kinase interacting serine/threonine kinase 1 [Homo sapiens] | | Outcome | |||
| 96 | %Inhibition(MKNK1) (10μM**) | 176 | | Float | % | |||
| 97 | Outcome(MKNK2) | 177 | map kinase-interacting kinase [Homo sapiens] | | Outcome | |||
| 98 | %Inhibition(MKNK2) (10μM**) | 177 | | Float | % | |||
| 99 | Outcome(MST1) | 184 | serine/threonine kinase 4 [Homo sapiens] | | Outcome | |||
| 100 | %Inhibition(MST1) (10μM**) | 184 | | Float | % | |||
| 101 | Outcome(MST2) | 185 | serine/threonine kinase 3 (STE20 homolog, yeast) [Homo sapiens] | | Outcome | |||
| 102 | %Inhibition(MST2) (10μM**) | 185 | | Float | % | |||
| 103 | Outcome(MUSK) | 188 | skeletal muscle receptor tyrosine kinase [Homo sapiens] | | Outcome | |||
| 104 | %Inhibition(MUSK) (10μM**) | 188 | | Float | % | |||
| 105 | Outcome(PDGFRA) | 213 | platelet-derived growth factor receptor alpha precursor [Homo sapiens] | | Outcome | |||
| 106 | %Inhibition(PDGFRA) (10μM**) | 213 | | Float | % | |||
| 107 | Outcome(PDGFRB) | 214 | platelet-derived growth factor receptor beta precursor [Homo sapiens] | | Outcome | |||
| 108 | %Inhibition(PDGFRB) (10μM**) | 214 | | Float | % | |||
| 109 | Outcome(PKAC-alpha) | 226 | cAMP-dependent protein kinase catalytic subunit alpha isoform 1 [Homo sapiens] | | Outcome | |||
| 110 | %Inhibition(PKAC-alpha) (10μM**) | 226 | | Float | % | |||
| 111 | Outcome(PLK3) | 232 | polo-like kinase 3 [Homo sapiens] | | Outcome | |||
| 112 | %Inhibition(PLK3) (10μM**) | 232 | | Float | % | |||
| 113 | Outcome(RET) | 249 | ret proto-oncogene isoform c [Homo sapiens] | | Outcome | |||
| 114 | %Inhibition(RET) (10μM**) | 249 | | Float | % | |||
| 115 | Outcome(RET(M918T)) | 250 | ret proto-oncogene isoform c [Homo sapiens] | | Outcome | |||
| 116 | %Inhibition(RET(M918T)) (10μM**) | 250 | | Float | % | |||
| 117 | Outcome(RIPK1) | 253 | receptor (TNFRSF)-interacting serine-threonine kinase 1 [Homo sapiens] | | Outcome | |||
| 118 | %Inhibition(RIPK1) (10μM**) | 253 | | Float | % | |||
| 119 | Outcome(SLK) | 257 | serine/threonine kinase 2 [Homo sapiens] | | Outcome | |||
| 120 | %Inhibition(SLK) (10μM**) | 257 | | Float | % | |||
| 121 | Outcome(STK33) | 266 | serine/threonine kinase 33 [Homo sapiens] | | Outcome | |||
| 122 | %Inhibition(STK33) (10μM**) | 266 | | Float | % | |||
| 123 | Outcome(TIE1) | 273 | tyrosine kinase with immunoglobulin-like and EGF-like domains 1 [Homo sapiens] | | Outcome | |||
| 124 | %Inhibition(TIE1) (10μM**) | 273 | | Float | % | |||
| 125 | Outcome(TIE2) | 274 | TEK tyrosine kinase, endothelial precursor [Homo sapiens] | | Outcome | |||
| 126 | %Inhibition(TIE2) (10μM**) | 274 | | Float | % | |||
| 127 | Outcome(TRKA) | 281 | neurotrophic tyrosine kinase, receptor, type 1 isoform 1 [Homo sapiens] | | Outcome | |||
| 128 | %Inhibition(TRKA) (10μM**) | 281 | | Float | % | |||
| 129 | Outcome(TRKB) | 282 | neurotrophic tyrosine kinase, receptor, type 2 isoform a precursor [Homo sapiens] | | Outcome | |||
| 130 | %Inhibition(TRKB) (10μM**) | 282 | | Float | % | |||
| 131 | Outcome(TRKC) | 283 | TrkC | | Outcome | |||
| 132 | %Inhibition(TRKC) (10μM**) | 283 | | Float | % | |||
| 133 | Outcome(VEGFR2) | 288 | kinase insert domain receptor (a type III receptor tyrosine kinase) [Homo sapiens] | | Outcome | |||
| 134 | %Inhibition(VEGFR2) (10μM**) | 288 | | Float | % | |||
| 135 | Outcome(YANK2) | 290 | serine/threonine kinase 32B [Homo sapiens] | | Outcome | |||
| 136 | %Inhibition(YANK2) (10μM**) | 290 | | Float | % | |||
| 137 | Outcome(ABL1) | 2 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 138 | %Inhibition(ABL1) (10μM**) | 2 | | Float | % | |||
| 139 | Outcome(BLK) | 30 | B lymphoid tyrosine kinase [Homo sapiens] | | Outcome | |||
| 140 | %Inhibition(BLK) (10μM**) | 30 | | Float | % | |||
| 141 | Outcome(BRAF) | 34 | v-raf murine sarcoma viral oncogene homolog B1 [Homo sapiens] | | Outcome | |||
| 142 | %Inhibition(BRAF) (10μM**) | 34 | | Float | % | |||
| 143 | Outcome(BRAF(V600E)) | 35 | v-raf murine sarcoma viral oncogene homolog B1 [Homo sapiens] | | Outcome | |||
| 144 | %Inhibition(BRAF(V600E)) (10μM**) | 35 | | Float | % | |||
| 145 | Outcome(CIT) | 59 | citron [Homo sapiens] | | Outcome | |||
| 146 | %Inhibition(CIT) (10μM**) | 59 | | Float | % | |||
| 147 | Outcome(EGFR) | 88 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 148 | %Inhibition(EGFR) (10μM**) | 88 | | Float | % | |||
| 149 | Outcome(EGFR(G719S)) | 91 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 150 | %Inhibition(EGFR(G719S)) (10μM**) | 91 | | Float | % | |||
| 151 | Outcome(EGFR(L861Q)) | 93 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 152 | %Inhibition(EGFR(L861Q)) (10μM**) | 93 | | Float | % | |||
| 153 | Outcome(FGFR1) | 117 | fibroblast growth factor receptor 1 isoform 3 precursor [Homo sapiens] | | Outcome | |||
| 154 | %Inhibition(FGFR1) (10μM**) | 117 | | Float | % | |||
| 155 | Outcome(FGFR4) | 121 | fibroblast growth factor receptor 4 isoform 2 precursor [Homo sapiens] | | Outcome | |||
| 156 | %Inhibition(FGFR4) (10μM**) | 121 | | Float | % | |||
| 157 | Outcome(FGR) | 122 | proto-oncogene tyrosine-protein kinase FGR [Homo sapiens] | | Outcome | |||
| 158 | %Inhibition(FGR) (10μM**) | 122 | | Float | % | |||
| 159 | Outcome(FYN) | 131 | protein-tyrosine kinase fyn isoform b [Homo sapiens] | | Outcome | |||
| 160 | %Inhibition(FYN) (10μM**) | 131 | | Float | % | |||
| 161 | Outcome(LCK) | 150 | lymphocyte-specific protein tyrosine kinase precursor [Homo sapiens] | | Outcome | |||
| 162 | %Inhibition(LCK) (10μM**) | 150 | | Float | % | |||
| 163 | Outcome(LYN) | 156 | Yamaguchi sarcoma viral (v-yes-1) oncogene homolog isoform A [Homo sapiens] | | Outcome | |||
| 164 | %Inhibition(LYN) (10μM**) | 156 | | Float | % | |||
| 165 | Outcome(PTK6) | 247 | PTK6 protein tyrosine kinase 6 [Homo sapiens] | | Outcome | |||
| 166 | %Inhibition(PTK6) (10μM**) | 247 | | Float | % | |||
| 167 | Outcome(RAF1) | 248 | v-raf-1 murine leukemia viral oncogene homolog 1 [Homo sapiens] | | Outcome | |||
| 168 | %Inhibition(RAF1) (10μM**) | 248 | | Float | % | |||
| 169 | Outcome(TNNI3K) | 280 | TNNI3 interacting kinase isoform b [Homo sapiens] | | Outcome | |||
| 170 | %Inhibition(TNNI3K) (10μM**) | 280 | | Float | % | |||
| 171 | Outcome(ZAK) | 294 | MLK-related kinase isoform 2 [Homo sapiens] | | Outcome | |||
| 172 | %Inhibition(ZAK) (10μM**) | 294 | | Float | % | |||
| 173 | Outcome(ABL1(E255K)) | 3 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 174 | %Inhibition(ABL1(E255K)) (10μM**) | 3 | | Float | % | |||
| 175 | Outcome(ABL1(H396P)) | 4 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 176 | %Inhibition(ABL1(H396P)) (10μM**) | 4 | | Float | % | |||
| 177 | Outcome(ABL1(M351T)) | 5 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 178 | %Inhibition(ABL1(M351T)) (10μM**) | 5 | | Float | % | |||
| 179 | Outcome(ABL1(Q252H)) | 6 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 180 | %Inhibition(ABL1(Q252H)) (10μM**) | 6 | | Float | % | |||
| 181 | Outcome(ABL1(Y253F)) | 8 | v-abl Abelson murine leukemia viral oncogene homolog 1 isoform a [Homo sapiens] | | Outcome | |||
| 182 | %Inhibition(ABL1(Y253F)) (10μM**) | 8 | | Float | % | |||
| 183 | Outcome(ABL2) | 9 | v-abl Abelson murine leukemia viral oncogene homolog 2 isoform a [Homo sapiens] | | Outcome | |||
| 184 | %Inhibition(ABL2) (10μM**) | 9 | | Float | % | |||
| 185 | Outcome(AMPK-alpha1) | 21 | AMP-activated protein kinase alpha-1 [Homo sapiens] | | Outcome | |||
| 186 | %Inhibition(AMPK-alpha1) (10μM**) | 21 | | Float | % | |||
| 187 | Outcome(ANKK1) | 23 | ankyrin repeat and kinase domain containing 1 [Homo sapiens] | | Outcome | |||
| 188 | %Inhibition(ANKK1) (10μM**) | 23 | | Float | % | |||
| 189 | Outcome(CAMK1) | 39 | calcium/calmodulin-dependent protein kinase I [Homo sapiens] | | Outcome | |||
| 190 | %Inhibition(CAMK1) (10μM**) | 39 | | Float | % | |||
| 191 | Outcome(CAMK4) | 46 | calcium/calmodulin-dependent protein kinase IV [Homo sapiens] | | Outcome | |||
| 192 | %Inhibition(CAMK4) (10μM**) | 46 | | Float | % | |||
| 193 | Outcome(CAMKK1) | 47 | calcium/calmodulin-dependent protein kinase 1 alpha isoform a [Homo sapiens] | | Outcome | |||
| 194 | %Inhibition(CAMKK1) (10μM**) | 47 | | Float | % | |||
| 195 | Outcome(CAMKK2) | 48 | calcium/calmodulin-dependent protein kinase kinase 2 beta isoform 1 [Homo sapiens] | | Outcome | |||
| 196 | %Inhibition(CAMKK2) (10μM**) | 48 | | Float | % | |||
| 197 | Outcome(CDK2) | 52 | cyclin-dependent kinase 2 isoform 1 [Homo sapiens] | | Outcome | |||
| 198 | %Inhibition(CDK2) (10μM**) | 52 | | Float | % | |||
| 199 | Outcome(CDK3) | 53 | cyclin-dependent kinase 3 [Homo sapiens] | | Outcome | |||
| 200 | %Inhibition(CDK3) (10μM**) | 53 | | Float | % | |||
| 201 | Outcome(CDK5) | 54 | cyclin-dependent kinase 5 [Homo sapiens] | | Outcome | |||
| 202 | %Inhibition(CDK5) (10μM**) | 54 | | Float | % | |||
| 203 | Outcome(CLK2) | 61 | CDC-like kinase 2 [Homo sapiens] | | Outcome | |||
| 204 | %Inhibition(CLK2) (10μM**) | 61 | | Float | % | |||
| 205 | Outcome(CSK) | 65 | c-src tyrosine kinase [Homo sapiens] | | Outcome | |||
| 206 | %Inhibition(CSK) (10μM**) | 65 | | Float | % | |||
| 207 | Outcome(CSNK1D) | 67 | casein kinase 1, delta isoform 2 [Homo sapiens] | | Outcome | |||
| 208 | %Inhibition(CSNK1D) (10μM**) | 67 | | Float | % | |||
| 209 | Outcome(CSNK1E) | 68 | casein kinase 1 epsilon [Homo sapiens] | | Outcome | |||
| 210 | %Inhibition(CSNK1E) (10μM**) | 68 | | Float | % | |||
| 211 | Outcome(CSNK1G2) | 70 | casein kinase 1, gamma 2 [Homo sapiens] | | Outcome | |||
| 212 | %Inhibition(CSNK1G2) (10μM**) | 70 | | Float | % | |||
| 213 | Outcome(CSNK1G3) | 71 | casein kinase 1, gamma 3 isoform 1 [Homo sapiens] | | Outcome | |||
| 214 | %Inhibition(CSNK1G3) (10μM**) | 71 | | Float | % | |||
| 215 | Outcome(DAPK3) | 76 | death-associated protein kinase 3 [Homo sapiens] | | Outcome | |||
| 216 | %Inhibition(DAPK3) (10μM**) | 76 | | Float | % | |||
| 217 | Outcome(DLK) | 82 | mitogen-activated protein kinase kinase kinase 12 [Homo sapiens] | | Outcome | |||
| 218 | %Inhibition(DLK) (10μM**) | 82 | | Float | % | |||
| 219 | Outcome(EGFR(E746-A750del)) | 89 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 220 | %Inhibition(EGFR(E746-A750del)) (10μM**) | 89 | | Float | % | |||
| 221 | Outcome(EGFR(L858R)) | 92 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 222 | %Inhibition(EGFR(L858R)) (10μM**) | 92 | | Float | % | |||
| 223 | Outcome(EPHA2) | 96 | ephrin receptor EphA2 [Homo sapiens] | | Outcome | |||
| 224 | %Inhibition(EPHA2) (10μM**) | 96 | | Float | % | |||
| 225 | Outcome(EPHA4) | 98 | ephrin receptor EphA4 [Homo sapiens] | | Outcome | |||
| 226 | %Inhibition(EPHA4) (10μM**) | 98 | | Float | % | |||
| 227 | Outcome(EPHA5) | 99 | ephrin receptor EphA5 isoform a [Homo sapiens] | | Outcome | |||
| 228 | %Inhibition(EPHA5) (10μM**) | 99 | | Float | % | |||
| 229 | Outcome(EPHA8) | 102 | EPH receptor A8 isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 230 | %Inhibition(EPHA8) (10μM**) | 102 | | Float | % | |||
| 231 | Outcome(EPHB1) | 103 | ephrin receptor EphB1 precursor [Homo sapiens] | | Outcome | |||
| 232 | %Inhibition(EPHB1) (10μM**) | 103 | | Float | % | |||
| 233 | Outcome(EPHB2) | 104 | ephrin receptor EphB2 isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 234 | %Inhibition(EPHB2) (10μM**) | 104 | | Float | % | |||
| 235 | Outcome(FER) | 115 | fer (fps/fes related) tyrosine kinase [Homo sapiens] | | Outcome | |||
| 236 | %Inhibition(FER) (10μM**) | 115 | | Float | % | |||
| 237 | Outcome(FES) | 116 | V-FES feline sarcoma viral/V-FPS fujinami avian sarcoma viral oncogene homolog [Homo sapiens] | | Outcome | |||
| 238 | %Inhibition(FES) (10μM**) | 116 | | Float | % | |||
| 239 | Outcome(FGFR2) | 118 | fibroblast growth factor receptor 2 isoform 2 precursor [Homo sapiens] | | Outcome | |||
| 240 | %Inhibition(FGFR2) (10μM**) | 118 | | Float | % | |||
| 241 | Outcome(GAK) | 132 | cyclin G associated kinase [Homo sapiens] | | Outcome | |||
| 242 | %Inhibition(GAK) (10μM**) | 132 | | Float | % | |||
| 243 | Outcome(HCK) | 135 | hemopoietic cell kinase isoform p61HCK [Homo sapiens] | | Outcome | |||
| 244 | %Inhibition(HCK) (10μM**) | 135 | | Float | % | |||
| 245 | Outcome(ITK) | 141 | IL2-inducible T-cell kinase [Homo sapiens] | | Outcome | |||
| 246 | %Inhibition(ITK) (10μM**) | 141 | | Float | % | |||
| 247 | Outcome(JNK1) | 142 | mitogen-activated protein kinase 8 isoform JNK1 alpha1 [Homo sapiens] | | Outcome | |||
| 248 | %Inhibition(JNK1) (10μM**) | 142 | | Float | % | |||
| 249 | Outcome(JNK3) | 144 | mitogen-activated protein kinase 10 isoform 1 [Homo sapiens] | | Outcome | |||
| 250 | %Inhibition(JNK3) (10μM**) | 144 | | Float | % | |||
| 251 | Outcome(LATS1) | 148 | LATS homolog 1 [Homo sapiens] | | Outcome | |||
| 252 | %Inhibition(LATS1) (10μM**) | 148 | | Float | % | |||
| 253 | Outcome(MAP4K4) | 161 | mitogen-activated protein kinase kinase kinase kinase 4 isoform 2 [Homo sapiens] | | Outcome | |||
| 254 | %Inhibition(MAP4K4) (10μM**) | 161 | | Float | % | |||
| 255 | Outcome(MELK) | 173 | maternal embryonic leucine zipper kinase [Homo sapiens] | | Outcome | |||
| 256 | %Inhibition(MELK) (10μM**) | 173 | | Float | % | |||
| 257 | Outcome(MYLK2) | 190 | skeletal myosin light chain kinase [Homo sapiens] | | Outcome | |||
| 258 | %Inhibition(MYLK2) (10μM**) | 190 | | Float | % | |||
| 259 | Outcome(MYO3A) | 191 | myosin IIIA [Homo sapiens] | | Outcome | |||
| 260 | %Inhibition(MYO3A) (10μM**) | 191 | | Float | % | |||
| 261 | Outcome(MYO3B) | 192 | myosin IIIB isoform 2 [Homo sapiens] | | Outcome | |||
| 262 | %Inhibition(MYO3B) (10μM**) | 192 | | Float | % | |||
| 263 | Outcome(NEK5) | 196 | NIMA (never in mitosis gene a)-related kinase 5 [Homo sapiens] | | Outcome | |||
| 264 | %Inhibition(NEK5) (10μM**) | 196 | | Float | % | |||
| 265 | Outcome(NLK) | 200 | nemo-like kinase [Homo sapiens] | | Outcome | |||
| 266 | %Inhibition(NLK) (10μM**) | 200 | | Float | % | |||
| 267 | Outcome(PCTK1) | 210 | PCTAIRE protein kinase 1 [Homo sapiens] | | Outcome | |||
| 268 | %Inhibition(PCTK1) (10μM**) | 210 | | Float | % | |||
| 269 | Outcome(PCTK2) | 211 | serine/threonine protein kinase [Homo sapiens] | | Outcome | |||
| 270 | %Inhibition(PCTK2) (10μM**) | 211 | | Float | % | |||
| 271 | Outcome(PCTK3) | 212 | PCTAIRE protein kinase 3 isoform b [Homo sapiens] | | Outcome | |||
| 272 | %Inhibition(PCTK3) (10μM**) | 212 | | Float | % | |||
| 273 | Outcome(PFTK1) | 216 | PFTAIRE protein kinase 1 [Homo sapiens] | | Outcome | |||
| 274 | %Inhibition(PFTK1) (10μM**) | 216 | | Float | % | |||
| 275 | Outcome(PKAC-beta) | 227 | cAMP-dependent protein kinase catalytic subunit beta isoform 2 [Homo sapiens] | | Outcome | |||
| 276 | %Inhibition(PKAC-beta) (10μM**) | 227 | | Float | % | |||
| 277 | Outcome(PRKCQ) | 237 | protein kinase C, theta [Homo sapiens] | | Outcome | |||
| 278 | %Inhibition(PRKCQ) (10μM**) | 237 | | Float | % | |||
| 279 | Outcome(PRKD1) | 238 | protein kinase D1 [Homo sapiens] | | Outcome | |||
| 280 | %Inhibition(PRKD1) (10μM**) | 238 | | Float | % | |||
| 281 | Outcome(PRKD2) | 239 | protein kinase D2 isoform A [Homo sapiens] | | Outcome | |||
| 282 | %Inhibition(PRKD2) (10μM**) | 239 | | Float | % | |||
| 283 | Outcome(PRKD3) | 240 | protein kinase D3 [Homo sapiens] | | Outcome | |||
| 284 | %Inhibition(PRKD3) (10μM**) | 240 | | Float | % | |||
| 285 | Outcome(PRKR) | 243 | eukaryotic translation initiation factor 2-alpha kinase 2 [Homo sapiens] | | Outcome | |||
| 286 | %Inhibition(PRKR) (10μM**) | 243 | | Float | % | |||
| 287 | Outcome(PTK2B) | 246 | PTK2B protein tyrosine kinase 2 beta isoform b [Homo sapiens] | | Outcome | |||
| 288 | %Inhibition(PTK2B) (10μM**) | 246 | | Float | % | |||
| 289 | Outcome(RIPK2) | 254 | receptor-interacting serine-threonine kinase 2 [Homo sapiens] | | Outcome | |||
| 290 | %Inhibition(RIPK2) (10μM**) | 254 | | Float | % | |||
| 291 | Outcome(ROS1) | 255 | proto-oncogene c-ros-1 protein precursor [Homo sapiens] | | Outcome | |||
| 292 | %Inhibition(ROS1) (10μM**) | 255 | | Float | % | |||
| 293 | Outcome(SNF1LK) | 259 | SNF1-like kinase [Homo sapiens] | | Outcome | |||
| 294 | %Inhibition(SNF1LK) (10μM**) | 259 | | Float | % | |||
| 295 | Outcome(SRC) | 261 | proto-oncogene tyrosine-protein kinase SRC [Homo sapiens] | | Outcome | |||
| 296 | %Inhibition(SRC) (10μM**) | 261 | | Float | % | |||
| 297 | Outcome(SRMS) | 262 | src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites [Homo sapiens] | | Outcome | |||
| 298 | %Inhibition(SRMS) (10μM**) | 262 | | Float | % | |||
| 299 | Outcome(STK36) | 267 | serine/threonine kinase 36 [Homo sapiens] | | Outcome | |||
| 300 | %Inhibition(STK36) (10μM**) | 267 | | Float | % | |||
| 301 | Outcome(SYK) | 268 | spleen tyrosine kinase [Homo sapiens] | | Outcome | |||
| 302 | %Inhibition(SYK) (10μM**) | 268 | | Float | % | |||
| 303 | Outcome(TESK1) | 270 | testis-specific protein kinase 1 [Homo sapiens] | | Outcome | |||
| 304 | %Inhibition(TESK1) (10μM**) | 270 | | Float | % | |||
| 305 | Outcome(TGFBR2) | 272 | transforming growth factor, beta receptor II isoform B precursor [Homo sapiens] | | Outcome | |||
| 306 | %Inhibition(TGFBR2) (10μM**) | 272 | | Float | % | |||
| 307 | Outcome(TNIK) | 277 | TRAF2 and NCK interacting kinase [Homo sapiens] | | Outcome | |||
| 308 | %Inhibition(TNIK) (10μM**) | 277 | | Float | % | |||
| 309 | Outcome(TNK1) | 278 | TNK1 protein [Homo sapiens] | | Outcome | |||
| 310 | %Inhibition(TNK1) (10μM**) | 278 | | Float | % | |||
| 311 | Outcome(TTK) | 285 | TTK protein kinase [Homo sapiens] | | Outcome | |||
| 312 | %Inhibition(TTK) (10μM**) | 285 | | Float | % | |||
| 313 | Outcome(YES) | 292 | viral oncogene yes-1 homolog 1 [Homo sapiens] | | Outcome | |||
| 314 | %Inhibition(YES) (10μM**) | 292 | | Float | % | |||
| 315 | Outcome(YSK1) | 293 | serine/threonine kinase 25 [Homo sapiens] | | Outcome | |||
| 316 | %Inhibition(YSK1) (10μM**) | 293 | | Float | % | |||
| 317 | Outcome(p38-alpha) | 201 | mitogen-activated protein kinase 14 isoform 2 [Homo sapiens] | | Outcome | |||
| 318 | %Inhibition(p38-alpha) (10μM**) | 201 | | Float | % | |||
| 319 | Outcome(p38-beta) | 202 | mitogen-activated protein kinase 11 [Homo sapiens] | | Outcome | |||
| 320 | %Inhibition(p38-beta) (10μM**) | 202 | | Float | % | |||
| 321 | Outcome(p38-gamma) | 203 | p38gamma MAP Kinase [Homo sapiens] | | Outcome | |||
| 322 | %Inhibition(p38-gamma) (10μM**) | 203 | | Float | % | |||
| 323 | Outcome(EGFR(S752-I759del)) | 94 | epidermal growth factor receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 324 | %Inhibition(EGFR(S752-I759del)) (10μM**) | 94 | | Float | % | |||
| 325 | Outcome(ERBB2) | 107 | erbB-2 isoform b [Homo sapiens] | | Outcome | |||
| 326 | %Inhibition(ERBB2) (10μM**) | 107 | | Float | % | |||
| 327 | Outcome(ERBB4) | 108 | v-erb-a erythroblastic leukemia viral oncogene homolog 4 isoform JM-a/CVT-2 precursor [Homo sapiens] | | Outcome | |||
| 328 | %Inhibition(ERBB4) (10μM**) | 108 | | Float | % | |||
| 329 | Outcome(MEK2) | 169 | mitogen-activated protein kinase kinase 2 [Homo sapiens] | | Outcome | |||
| 330 | %Inhibition(MEK2) (10μM**) | 169 | | Float | % | |||
| 331 | Outcome(PLK4) | 233 | Sak [Homo sapiens] | | Outcome | |||
| 332 | %Inhibition(PLK4) (10μM**) | 233 | | Float | % | |||
| 333 | Outcome(DMPK2) | 84 | CDC42 binding protein kinase gamma (DMPK-like) [Homo sapiens] | | Outcome | |||
| 334 | %Inhibition(DMPK2) (10μM**) | 84 | | Float | % | |||
| 335 | Outcome(EPHA1) | 95 | ephrin receptor EphA1 [Homo sapiens] | | Outcome | |||
| 336 | %Inhibition(EPHA1) (10μM**) | 95 | | Float | % | |||
| 337 | Outcome(MRCKA) | 182 | CDC42-binding protein kinase alpha isoform B [Homo sapiens] | | Outcome | |||
| 338 | %Inhibition(MRCKA) (10μM**) | 182 | | Float | % | |||
| 339 | Outcome(MRCKB) | 183 | CDC42-binding protein kinase beta [Homo sapiens] | | Outcome | |||
| 340 | %Inhibition(MRCKB) (10μM**) | 183 | | Float | % | |||
| 341 | Outcome(PTK2) | 245 | PTK2 protein tyrosine kinase 2 isoform a [Homo sapiens] | | Outcome | |||
| 342 | %Inhibition(PTK2) (10μM**) | 245 | | Float | % | |||
| 343 | Outcome(DCAMKL1) | 77 | doublecortin and CaM kinase-like 1 [Homo sapiens] | | Outcome | |||
| 344 | %Inhibition(DCAMKL1) (10μM**) | 77 | | Float | % | |||
| 345 | Outcome(DCAMKL2) | 78 | doublecortin and CaM kinase-like 2 isoform b [Homo sapiens] | | Outcome | |||
| 346 | %Inhibition(DCAMKL2) (10μM**) | 78 | | Float | % | |||
| 347 | Outcome(DCAMKL3) | 79 | PREDICTED: similar to doublecortin and CaM kinase-like 3 [Homo sapiens] | | Outcome | |||
| 348 | %Inhibition(DCAMKL3) (10μM**) | 79 | | Float | % | |||
| 349 | Outcome(DRAK1) | 85 | serine/threonine kinase 17a [Homo sapiens] | | Outcome | |||
| 350 | %Inhibition(DRAK1) (10μM**) | 85 | | Float | % | |||
| 351 | Outcome(DYRK1B) | 87 | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B isoform a [Homo sapiens] | | Outcome | |||
| 352 | %Inhibition(DYRK1B) (10μM**) | 87 | | Float | % | |||
| 353 | Outcome(ERK3) | 111 | mitogen-activated protein kinase 6 [Homo sapiens] | | Outcome | |||
| 354 | %Inhibition(ERK3) (10μM**) | 111 | | Float | % | |||
| 355 | Outcome(ERK4) | 112 | mitogen-activated protein kinase 4 [Homo sapiens] | | Outcome | |||
| 356 | %Inhibition(ERK4) (10μM**) | 112 | | Float | % | |||
| 357 | Outcome(ERK5) | 113 | mitogen-activated protein kinase 7 isoform 1 [Homo sapiens] | | Outcome | |||
| 358 | %Inhibition(ERK5) (10μM**) | 113 | | Float | % | |||
| 359 | Outcome(GSK3A) | 133 | glycogen synthase kinase 3 alpha [Homo sapiens] | | Outcome | |||
| 360 | %Inhibition(GSK3A) (10μM**) | 133 | | Float | % | |||
| 361 | Outcome(GSK3B) | 134 | glycogen synthase kinase 3 beta [Homo sapiens] | | Outcome | |||
| 362 | %Inhibition(GSK3B) (10μM**) | 134 | | Float | % | |||
| 363 | Outcome(IRAK3) | 140 | interleukin-1 receptor-associated kinase 3 [Homo sapiens] | | Outcome | |||
| 364 | %Inhibition(IRAK3) (10μM**) | 140 | | Float | % | |||
| 365 | Outcome(MLCK) | 178 | myosin light chain kinase 3 [Homo sapiens] | | Outcome | |||
| 366 | %Inhibition(MLCK) (10μM**) | 178 | | Float | % | |||
| 367 | Outcome(PAK3) | 206 | p21-activated kinase 3 isoform a [Homo sapiens] | | Outcome | |||
| 368 | %Inhibition(PAK3) (10μM**) | 206 | | Float | % | |||
| 369 | Outcome(PHKG1) | 217 | phosphorylase kinase gamma subunit 1 [Homo sapiens] | | Outcome | |||
| 370 | %Inhibition(PHKG1) (10μM**) | 217 | | Float | % | |||
| 371 | Outcome(SNARK) | 258 | NUAK family, SNF1-like kinase, 2 [Homo sapiens] | | Outcome | |||
| 372 | %Inhibition(SNARK) (10μM**) | 258 | | Float | % | |||
| 373 | Outcome(AAK1) | 1 | AP2 associated kinase 1 [Homo sapiens] | | Outcome | |||
| 374 | %Inhibition(AAK1) (10μM**) | 1 | | Float | % | |||
| 375 | Outcome(AMPK-alpha2) | 22 | AMP-activated protein kinase alpha 2 catalytic subunit [Homo sapiens] | | Outcome | |||
| 376 | %Inhibition(AMPK-alpha2) (10μM**) | 22 | | Float | % | |||
| 377 | Outcome(ARK5) | 24 | AMPK-related protein kinase 5 [Homo sapiens] | | Outcome | |||
| 378 | %Inhibition(ARK5) (10μM**) | 24 | | Float | % | |||
| 379 | Outcome(BIKE) | 29 | BMP-2 inducible kinase isoform b [Homo sapiens] | | Outcome | |||
| 380 | %Inhibition(BIKE) (10μM**) | 29 | | Float | % | |||
| 381 | Outcome(CHEK1) | 58 | CHK1 checkpoint homolog [Homo sapiens] | | Outcome | |||
| 382 | %Inhibition(CHEK1) (10μM**) | 58 | | Float | % | |||
| 383 | Outcome(CSNK2A1) | 72 | casein kinase II alpha 1 subunit isoform a [Homo sapiens] | | Outcome | |||
| 384 | %Inhibition(CSNK2A1) (10μM**) | 72 | | Float | % | |||
| 385 | Outcome(CSNK2A2) | 73 | casein kinase 2, alpha prime polypeptide [Homo sapiens] | | Outcome | |||
| 386 | %Inhibition(CSNK2A2) (10μM**) | 73 | | Float | % | |||
| 387 | Outcome(DRAK2) | 86 | serine/threonine kinase 17b [Homo sapiens] | | Outcome | |||
| 388 | %Inhibition(DRAK2) (10μM**) | 86 | | Float | % | |||
| 389 | Outcome(FGFR3) | 119 | fibroblast growth factor receptor 3 isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 390 | %Inhibition(FGFR3) (10μM**) | 119 | | Float | % | |||
| 391 | Outcome(FGFR3(G697C)) | 120 | fibroblast growth factor receptor 3 isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 392 | %Inhibition(FGFR3(G697C)) (10μM**) | 120 | | Float | % | |||
| 393 | Outcome(IKK-epsilon) | 137 | IKK-related kinase epsilon [Homo sapiens] | | Outcome | |||
| 394 | %Inhibition(IKK-epsilon) (10μM**) | 137 | | Float | % | |||
| 395 | Outcome(LKB1) | 153 | serine/threonine protein kinase 11 [Homo sapiens] | | Outcome | |||
| 396 | %Inhibition(LKB1) (10μM**) | 153 | | Float | % | |||
| 397 | Outcome(MAP3K4) | 157 | mitogen-activated protein kinase kinase kinase 4 isoform a [Homo sapiens] | | Outcome | |||
| 398 | %Inhibition(MAP3K4) (10μM**) | 157 | | Float | % | |||
| 399 | Outcome(MARK1) | 164 | MAP/microtubule affinity-regulating kinase 1 [Homo sapiens] | | Outcome | |||
| 400 | %Inhibition(MARK1) (10μM**) | 164 | | Float | % | |||
| 401 | Outcome(MARK2) | 165 | MAP/microtubule affinity-regulating kinase 2 isoform a [Homo sapiens] | | Outcome | |||
| 402 | %Inhibition(MARK2) (10μM**) | 165 | | Float | % | |||
| 403 | Outcome(MARK3) | 166 | MAP/microtubule affinity-regulating kinase 3 isoform c [Homo sapiens] | | Outcome | |||
| 404 | %Inhibition(MARK3) (10μM**) | 166 | | Float | % | |||
| 405 | Outcome(MARK4) | 167 | MAP/microtubule affinity-regulating kinase 4 [Homo sapiens] | | Outcome | |||
| 406 | %Inhibition(MARK4) (10μM**) | 167 | | Float | % | |||
| 407 | Outcome(MEK1) | 168 | mitogen-activated protein kinase kinase 1 [Homo sapiens] | | Outcome | |||
| 408 | %Inhibition(MEK1) (10μM**) | 168 | | Float | % | |||
| 409 | Outcome(MLK1) | 179 | mitogen-activated protein kinase kinase kinase 9 [Homo sapiens] | | Outcome | |||
| 410 | %Inhibition(MLK1) (10μM**) | 179 | | Float | % | |||
| 411 | Outcome(MLK3) | 181 | mitogen-activated protein kinase kinase kinase 11 [Homo sapiens] | | Outcome | |||
| 412 | %Inhibition(MLK3) (10μM**) | 181 | | Float | % | |||
| 413 | Outcome(MST3) | 186 | serine/threonine kinase 24 isoform a [Homo sapiens] | | Outcome | |||
| 414 | %Inhibition(MST3) (10μM**) | 186 | | Float | % | |||
| 415 | Outcome(MST4) | 187 | serine/threonine protein kinase MST4 isoform 1 [Homo sapiens] | | Outcome | |||
| 416 | %Inhibition(MST4) (10μM**) | 187 | | Float | % | |||
| 417 | Outcome(MYLK) | 189 | myosin light chain kinase isoform 2 [Homo sapiens] | | Outcome | |||
| 418 | %Inhibition(MYLK) (10μM**) | 189 | | Float | % | |||
| 419 | Outcome(NEK2) | 195 | NIMA (never in mitosis gene a)-related kinase 2 [Homo sapiens] | | Outcome | |||
| 420 | %Inhibition(NEK2) (10μM**) | 195 | | Float | % | |||
| 421 | Outcome(NEK6) | 197 | putative serine-threonine protein kinase [Homo sapiens] | | Outcome | |||
| 422 | %Inhibition(NEK6) (10μM**) | 197 | | Float | % | |||
| 423 | Outcome(NEK7) | 198 | NIMA (never in mitosis gene a)-related kinase 7 [Homo sapiens] | | Outcome | |||
| 424 | %Inhibition(NEK7) (10μM**) | 198 | | Float | % | |||
| 425 | Outcome(NEK9) | 199 | NIMA related kinase 9 [Homo sapiens] | | Outcome | |||
| 426 | %Inhibition(NEK9) (10μM**) | 199 | | Float | % | |||
| 427 | Outcome(PHKG2) | 218 | phosphorylase kinase, gamma 2 (testis) [Homo sapiens] | | Outcome | |||
| 428 | %Inhibition(PHKG2) (10μM**) | 218 | | Float | % | |||
| 429 | Outcome(PIP5K1A) | 224 | 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha [Homo sapiens] | | Outcome | |||
| 430 | %Inhibition(PIP5K1A) (10μM**) | 224 | | Float | % | |||
| 431 | Outcome(PIP5K2B) | 225 | phosphatidylinositol-5-phosphate 4-kinase, type II, beta [Homo sapiens] | | Outcome | |||
| 432 | %Inhibition(PIP5K2B) (10μM**) | 225 | | Float | % | |||
| 433 | Outcome(PKN1) | 229 | protein kinase N1 isoform 1 [Homo sapiens] | | Outcome | |||
| 434 | %Inhibition(PKN1) (10μM**) | 229 | | Float | % | |||
| 435 | Outcome(PKN2) | 230 | protein kinase N2 [Homo sapiens] | | Outcome | |||
| 436 | %Inhibition(PKN2) (10μM**) | 230 | | Float | % | |||
| 437 | Outcome(RIOK1) | 251 | RIO kinase 1 isoform 1 [Homo sapiens] | | Outcome | |||
| 438 | %Inhibition(RIOK1) (10μM**) | 251 | | Float | % | |||
| 439 | Outcome(RIOK3) | 252 | sudD suppressor of bimD6 homolog [Homo sapiens] | | Outcome | |||
| 440 | %Inhibition(RIOK3) (10μM**) | 252 | | Float | % | |||
| 441 | Outcome(SNF1LK2) | 260 | SNF1-like kinase 2 [Homo sapiens] | | Outcome | |||
| 442 | %Inhibition(SNF1LK2) (10μM**) | 260 | | Float | % | |||
| 443 | Outcome(SRPK1) | 263 | SFRS protein kinase 1 [Homo sapiens] | | Outcome | |||
| 444 | %Inhibition(SRPK1) (10μM**) | 263 | | Float | % | |||
| 445 | Outcome(SRPK2) | 264 | serine kinase SRPK2 [Homo sapiens] | | Outcome | |||
| 446 | %Inhibition(SRPK2) (10μM**) | 264 | | Float | % | |||
| 447 | Outcome(SgK085) | 256 | myosin light chain kinase family, member 4 [Homo sapiens] | | Outcome | |||
| 448 | %Inhibition(SgK085) (101μM**) | 256 | | Float | % | |||
| 449 | Outcome(TLK2) | 276 | tousled-like kinase 2 [Homo sapiens] | | Outcome | |||
| 450 | %Inhibition(TLK2) (10μM**) | 276 | | Float | % | |||
| 451 | Outcome(TYRO3) | 287 | TYRO3 protein tyrosine kinase [Homo sapiens] | | Outcome | |||
| 452 | %Inhibition(TYRO3) (10μM**) | 287 | | Float | % | |||
| 453 | Outcome(WEE1) | 289 | wee1 tyrosine kinase [Homo sapiens] | | Outcome | |||
| 454 | %Inhibition(WEE1) (10μM**) | 289 | | Float | % | |||
| 455 | Outcome(ACVR1) | 10 | activin A type I receptor precursor [Homo sapiens] | | Outcome | |||
| 456 | %Inhibition(ACVR1) (10μM**) | 10 | | Float | % | |||
| 457 | Outcome(ADCK3) | 15 | chaperone, ABC1 activity of bc1 complex like precursor [Homo sapiens] | | Outcome | |||
| 458 | %Inhibition(ADCK3) (10μM**) | 15 | | Float | % | |||
| 459 | Outcome(ADCK4) | 16 | aarF domain containing kinase 4 [Homo sapiens] | | Outcome | |||
| 460 | %Inhibition(ADCK4) (10μM**) | 16 | | Float | % | |||
| 461 | Outcome(BMX) | 33 | BMX non-receptor tyrosine kinase [Homo sapiens] | | Outcome | |||
| 462 | %Inhibition(BMX) (10μM**) | 33 | | Float | % | |||
| 463 | Outcome(BTK) | 38 | Bruton agammaglobulinemia tyrosine kinase [Homo sapiens] | | Outcome | |||
| 464 | %Inhibition(BTK) (10μM**) | 38 | | Float | % | |||
| 465 | Outcome(TEC) | 269 | tec protein tyrosine kinase [Homo sapiens] | | Outcome | |||
| 466 | %Inhibition(TEC) (10μM**) | 269 | | Float | % | |||
| 467 | Outcome(TGFBR1) | 271 | transforming growth factor, beta receptor I isoform 1 precursor [Homo sapiens] | | Outcome | |||
| 468 | %Inhibition(TGFBR1) (10μM**) | 271 | | Float | % | |||
| 469 | Outcome(TXK) | 286 | TXK tyrosine kinase [Homo sapiens] | | Outcome | |||
| 470 | %Inhibition(TXK) (10μM**) | 286 | | Float | % | |||
| 471 | Outcome(ACVR1B) | 11 | activin A type IB receptor isoform a precursor [Homo sapiens] | | Outcome | |||
| 472 | %Inhibition(ACVR1B) (10μM**) | 11 | | Float | % | |||
| 473 | Outcome(ACVR2A) | 12 | activin A receptor, type IIA precursor [Homo sapiens] | | Outcome | |||
| 474 | %Inhibition(ACVR2A) (10μM**) | 12 | | Float | % | |||
| 475 | Outcome(ACVR2B) | 13 | activin A type IIB receptor precursor [Homo sapiens] | | Outcome | |||
| 476 | %Inhibition(ACVR2B) (10μM**) | 13 | | Float | % | |||
| 477 | Outcome(ACVRL1) | 14 | activin A receptor type II-like 1 [Homo sapiens] | | Outcome | |||
| 478 | %Inhibition(ACVRL1) (10μM**) | 14 | | Float | % | |||
| 479 | Outcome(DMPK) | 83 | myotonic dystrophy protein kinase isoform 2 [Homo sapiens] | | Outcome | |||
| 480 | %Inhibition(DMPK) (10μM**) | 83 | | Float | % | |||
| 481 | Outcome(LIMK1) | 151 | LIM domain kinase 1 [Homo sapiens] | | Outcome | |||
| 482 | %Inhibition(LIMK1) (10μM**) | 151 | | Float | % | |||
| 483 | Outcome(PKMYT1) | 228 | protein kinase Myt1 isoform 2 [Homo sapiens] | | Outcome | |||
| 484 | %Inhibition(PKMYT1) (10μM**) | 228 | | Float | % | |||
| 485 | Outcome(TNK2) | 279 | tyrosine kinase, non-receptor, 2 isoform 2 [Homo sapiens] | | Outcome | |||
| 486 | %Inhibition(TNK2) (10μM**) | 279 | | Float | % | |||
| 487 | Outcome(CAMK1D) | 40 | calcium/calmodulin-dependent protein kinase ID isoform 1 [Homo sapiens] | | Outcome | |||
| 488 | %Inhibition(CAMK1D) (10μM**) | 40 | | Float | % | |||
| 489 | Outcome(CLK3) | 62 | CDC-like kinase 3 isoform b [Homo sapiens] | | Outcome | |||
| 490 | %Inhibition(CLK3) (10μM**) | 62 | | Float | % | |||
| 491 | Outcome(CSNK1A1L) | 66 | casein kinase 1, alpha 1-like [Homo sapiens] | | Outcome | |||
| 492 | %Inhibition(CSNK1A1L) (10μM**) | 66 | | Float | % | |||
| 493 | Outcome(NEK1) | 194 | NIMA (never in mitosis gene a)-related kinase 1 [Homo sapiens] | | Outcome | |||
| 494 | %Inhibition(NEK1) (10μM**) | 194 | | Float | % | |||
| 495 | Outcome(PAK1) | 204 | p21-activated kinase 1 isoform 2 [Homo sapiens] | | Outcome | |||
| 496 | %Inhibition(PAK1) (10μM**) | 204 | | Float | % | |||
| 497 | Outcome(PRKCD) | 234 | protein kinase C, delta [Homo sapiens] | | Outcome | |||
| 498 | %Inhibition(PRKCD) (10μM**) | 234 | | Float | % | |||
| 499 | Outcome(CAMK2A) | 42 | calcium/calmodulin-dependent protein kinase IIA isoform 2 [Homo sapiens] | | Outcome | |||
| 500 | %Inhibition(CAMK2A) (10μM**) | 42 | | Float | % | |||
| 501 | Outcome(MLK2) | 180 | mitogen-activated protein kinase kinase kinase 10 [Homo sapiens] | | Outcome | |||
| 502 | %Inhibition(MLK2) (10μM**) | 180 | | Float | % | |||
| 503 | Outcome(PIM1) | 221 | pim-1 oncogene [Homo sapiens] | | Outcome | |||
| 504 | %Inhibition(PIM1) (10μM**) | 221 | | Float | % | |||
| 505 | Outcome(PIM2) | 222 | pim-2 oncogene [Homo sapiens] | | Outcome | |||
| 506 | %Inhibition(PIM2) (10μM**) | 222 | | Float | % | |||
| 507 | Outcome(PIM3) | 223 | pim-3 oncogene [Homo sapiens] | | Outcome | |||
| 508 | %Inhibition(PIM3) (10μM**) | 223 | | Float | % | |||
| 509 | Outcome(PRKCE) | 235 | protein kinase C, epsilon [Homo sapiens] | | Outcome | |||
| 510 | %Inhibition(PRKCE) (10μM**) | 235 | | Float | % | |||
| 511 | Outcome(PRKCH) | 236 | protein kinase C, eta [Homo sapiens] | | Outcome | |||
| 512 | %Inhibition(PRKCH) (10μM**) | 236 | | Float | % | |||
| 513 | Outcome(CAMK1G) | 41 | calcium/calmodulin-dependent protein kinase IG [Homo sapiens] | | Outcome | |||
| 514 | %Inhibition(CAMK1G) (10μM**) | 41 | | Float | % | |||
| 515 | Outcome(MEK4) | 171 | mitogen-activated protein kinase kinase 4 [Homo sapiens] | | Outcome | |||
| 516 | %Inhibition(MEK4) (10μM**) | 171 | | Float | % | |||
| 517 | Outcome(MEK6) | 172 | mitogen-activated protein kinase kinase 6 [Homo sapiens] | | Outcome | |||
| 518 | %Inhibition(MEK6) (10μM**) | 172 | | Float | % | |||
| 519 | Outcome(STK16) | 265 | PKL12 protein [Homo sapiens] | | Outcome | |||
| 520 | %Inhibition(STK16) (10μM**) | 265 | | Float | % | |||
| 521 | Outcome(BRSK1) | 36 | BR serine/threonine kinase 1 [Homo sapiens] | | Outcome | |||
| 522 | %Inhibition(BRSK1) (10μM**) | 36 | | Float | % | |||
| 523 | Outcome(BRSK2) | 37 | BR serine/threonine kinase 2 [Homo sapiens] | | Outcome | |||
| 524 | %Inhibition(BRSK2) (10μM**) | 37 | | Float | % | |||
| 525 | Outcome(CSNK1G1) | 69 | casein kinase 1, gamma 1 [Homo sapiens] | | Outcome | |||
| 526 | %Inhibition(CSNK1G1) (10μM**) | 69 | | Float | % | |||
| 527 | Outcome(MEK3) | 170 | mitogen-activated protein kinase kinase 3 isoform A [Homo sapiens] | | Outcome | |||
| 528 | %Inhibition(MEK3) (10μM**) | 170 | | Float | % | |||
| 529 | Outcome(PAK4) | 207 | p21-activated kinase 4 isoform 3 [Homo sapiens] | | Outcome | |||
| 530 | %Inhibition(PAK4) (10μM**) | 207 | | Float | % | |||
| 531 | Outcome(PAK6) | 208 | p21-activated kinase 6 [Homo sapiens] | | Outcome | |||
| 532 | %Inhibition(PAK6) (10μM**) | 208 | | Float | % | |||
| 533 | Outcome(PAK7/PAK5) | 209 | p21-activated kinase 7 [Homo sapiens] | | Outcome | |||
| 534 | %Inhibition(PAK7/PAK5) (10μM**) | 209 | | Float | % | |||
| 535 | Outcome(PDPK1) | 215 | 3-phosphoinositide dependent protein kinase-1 isoform 1 [Homo sapiens] | | Outcome | |||
| 536 | %Inhibition(PDPK1) (10μM**) | 215 | | Float | % | |||
| 537 | Outcome(PLK1) | 231 | polo-like kinase [Homo sapiens] | | Outcome | |||
| 538 | %Inhibition(PLK1) (10μM**) | 231 | | Float | % | |||
| 539 | Outcome(TLK1) | 275 | tousled-like kinase 1 [Homo sapiens] | | Outcome | |||
| 540 | %Inhibition(TLK1) (10μM**) | 275 | | Float | % | |||
| 541 | Outcome(AKT3) | 19 | v-akt murine thymoma viral oncogene homolog 3 isoform 1 [Homo sapiens] | | Outcome | |||
| 542 | %Inhibition(AKT3) (10μM**) | 19 | | Float | % | |||
| 543 | Outcome(CAMK2D) | 44 | multifunctional calcium/calmodulin-dependent protein kinase II delta2 isoform [Homo sapiens] | | Outcome | |||
| 544 | %Inhibition(CAMK2D) (10μM**) | 44 | | Float | % | |||
| 545 | Outcome(CAMK2G) | 45 | calcium/calmodulin-dependent protein kinase II gamma isoform 6 [Homo sapiens] | | Outcome | |||
| 546 | %Inhibition(CAMK2G) (10μM**) | 45 | | Float | % | |||
| 547 | Outcome(DAPK1) | 74 | death-associated protein kinase 1 [Homo sapiens] | | Outcome | |||
| 548 | %Inhibition(DAPK1) (10μM**) | 74 | | Float | % | |||
| 549 | Outcome(PRKG2) | 242 | protein kinase, cGMP-dependent, type II [Homo sapiens] | | Outcome | |||
| 550 | %Inhibition(PRKG2) (10μM**) | 242 | | Float | % | |||
| 551 | Outcome(DAPK2) | 75 | death-associated protein kinase 2 [Homo sapiens] | | Outcome | |||
| 552 | %Inhibition(DAPK2) (10μM**) | 75 | | Float | % | |||
| 553 | Outcome(PIK3CA) | 219 | phosphoinositide-3-kinase, catalytic, alpha polypeptide [Homo sapiens] | | Outcome | |||
| 554 | %Inhibition(PIK3CA) (10μM**) | 219 | | Float | % | |||
| 555 | Outcome(PIK3CA(E545K)) | 220 | phosphoinositide-3-kinase, catalytic, alpha polypeptide [Homo sapiens] | | Outcome | |||
| 556 | %Inhibition(PIK3CA(E545K)) (10μM**) | 220 | | Float | % | |||
| 557 | Outcome(AKT1) | 17 | v-akt murine thymoma viral oncogene homolog 1 [Homo sapiens] | | Outcome | |||
| 558 | %Inhibition(AKT1) (10μM**) | 17 | | Float | % | |||
| 559 | Outcome(AKT2) | 18 | v-akt murine thymoma viral oncogene homolog 2 [Homo sapiens] | | Outcome | |||
| 560 | %Inhibition(AKT2) (10μM**) | 18 | | Float | % | |||
| 561 | Outcome(CAMK2B) | 43 | calcium/calmodulin-dependent protein kinase IIB isoform 1 [Homo sapiens] | | Outcome | |||
| 562 | %Inhibition(CAMK2B) (10μM**) | 43 | | Float | % | |||
| 563 | Outcome(PAK2) | 205 | p21-activated kinase 2 [Homo sapiens] | | Outcome | |||
| 564 | %Inhibition(PAK2) (10μM**) | 205 | | Float | % | |||
| 565 | Outcome(PRKG1) | 241 | protein kinase, cGMP-dependent, type I isoform 2 [Homo sapiens] | | Outcome | |||
| 566 | %Inhibition(PRKG1) (10μM**) | 241 | | Float | % | |||
| 567 | Outcome(PRKX) | 244 | protein kinase, X-linked [Homo sapiens] | | Outcome | |||
| 568 | %Inhibition(PRKX) (10μM**) | 244 | | Float | % | |||
| 569 | Outcome(TSSK1) | 284 | testis-specific serine kinase 1 [Homo sapiens] | | Outcome | |||
| 570 | %Inhibition(TSSK1) (10μM**) | 284 | | Float | % | |||
| 571 | Outcome(ZAP70) | 295 | zeta-chain associated protein kinase 70kDa isoform 2 [Homo sapiens] | | Outcome | |||
| 572 | %Inhibition(ZAP70) (10μM**) | 295 | | Float | % | |||
| 573 | Outcome(INSR) | 138 | insulin receptor isoform Long precursor [Homo sapiens] | | Outcome | |||
| 574 | %Inhibition(INSR) (10μM**) | 138 | | Float | % | |||
| 575 | Outcome(NDR2) | 193 | serine/threonine kinase 38 like [Homo sapiens] | | Outcome | |||
| 576 | %Inhibition(NDR2) (10μM**) | 193 | | Float | % | |||
| 577 | Outcome(BMPR1A) | 31 | bone morphogenetic protein receptor, type IA precursor [Homo sapiens] | | Outcome | |||
| 578 | %Inhibition(BMPR1A) (10μM**) | 31 | | Float | % | |||
| 579 | Outcome(ERK1) | 109 | mitogen-activated protein kinase 3 isoform 1 [Homo sapiens] | | Outcome | |||
| 580 | %Inhibition(ERK1) (10μM**) | 109 | | Float | % | |||
| 581 | Outcome(ERK2) | 110 | mitogen-activated protein kinase 1 [Homo sapiens] | | Outcome | |||
| 582 | %Inhibition(ERK2) (10μM**) | 110 | | Float | % | |||
| 583 | Outcome(IGF1R) | 136 | insulin-like growth factor 1 receptor precursor [Homo sapiens] | | Outcome | |||
| 584 | %Inhibition(IGF1R) (10μM**) | 136 | | Float | % | |||
| 585 | Outcome(MAP3K5) | 158 | mitogen-activated protein kinase kinase kinase 5 [Homo sapiens] | | Outcome | |||
| 586 | %Inhibition(MAP3K5) (10μM**) | 158 | | Float | % | |||
| 587 | Outcome(MAPKAPK2) | 163 | mitogen-activated protein kinase-activated protein kinase 2 isoform 2 [Homo sapiens] | | Outcome | |||
| 588 | %Inhibition(MAPKAPK2) (10μM**) | 163 | | Float | % | |||
| 589 | Outcome(YANK3) | 291 | serine/threonine kinase 32C [Homo sapiens] | | Outcome | |||
| 590 | %Inhibition(YANK3) (10μM**) | 291 | | Float | % | |||
| 591 | Outcome(ABL1(F317I)) | 296 | c-abl oncogene 1, receptor tyrosine kinase | | Outcome | |||
| 592 | %Inhibition(ABL1(F317I)) (10μM**) | 296 | | Float | % | |||
| 593 | Outcome(ABL1(F317L)) | 297 | c-abl oncogene 1, receptor tyrosine kinase | | Outcome | |||
| 594 | %Inhibition(ABL1(F317L)) (10μM**) | 297 | | Float | % | |||
| 595 | Outcome(BMPR1B) | 298 | bone morphogenetic protein receptor, type IB | | Outcome | |||
| 596 | %Inhibition(BMPR1B) (10μM**) | 298 | | Float | % | |||
| 597 | Outcome(CDKL2) | 299 | cyclin-dependent kinase-like 2 (CDC2-related kinase) | | Outcome | |||
| 598 | %Inhibition(CDKL2) (10μM**) | 299 | | Float | % | |||
| 599 | Outcome(CHEK2) | 300 | CHK2 checkpoint homolog (S. pombe) | | Outcome | |||
| 600 | %Inhibition(CHEK2) (10μM**) | 300 | | Float | % | |||
| 601 | Outcome(EGFR(L747-E749del, A750P)) | 301 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | | Outcome | |||
| 602 | %Inhibition(EGFR(L747-E749del, A750P)) (10μM**) | 301 | | Float | % | |||
| 603 | Outcome(EGFR(L747-S752del, P753S)) | 302 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | | Outcome | |||
| 604 | %Inhibition(EGFR(L747-S752del, P753S)) (10μM**) | 302 | | Float | % | |||
| 605 | Outcome(EGFR(L747-T751del,Sins)) | 303 | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | | Outcome | |||
| 606 | %Inhibition(EGFR(L747-T751del,Sins)) (10μM**) | 303 | | Float | % | |||
| 607 | Outcome(FLT3(K663Q)) | 304 | fms-related tyrosine kinase 3 | | Outcome | |||
| 608 | %Inhibition(FLT3(K663Q)) (10μM**) | 304 | | Float | % | |||
| 609 | Outcome(GCN2(Kin.Dom.2,S808G)) | 305 | eukaryotic translation initiation factor 2 alpha kinase 4 | | Outcome | |||
| 610 | %Inhibition(GCN2(Kin.Dom.2,S808G)) (10μM**) | 305 | | Float | % | |||
| 611 | Outcome(HIPK1) | 306 | homeodomain interacting protein kinase 1 | | Outcome | |||
| 612 | %Inhibition(HIPK1) (10μM**) | 306 | | Float | % | |||
| 613 | Outcome(IKK-alpha) | 307 | conserved helix-loop-helix ubiquitous kinase | | Outcome | |||
| 614 | %Inhibition(IKK-alpha) (10μM**) | 307 | | Float | % | |||
| 615 | Outcome(IKK-beta) | 308 | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | | Outcome | |||
| 616 | %Inhibition(IKK-beta) (10μM**) | 308 | | Float | % | |||
| 617 | Outcome(JAK1(Kin.Dom.1)) | 309 | Janus kinase 1 | | Outcome | |||
| 618 | %Inhibition(JAK1(Kin.Dom.1)) (10μM**) | 309 | | Float | % | |||
| 619 | Outcome(JAK1(Kin.Dom.2)) | 310 | Janus kinase 1 | | Outcome | |||
| 620 | %Inhibition(JAK1(Kin.Dom.2)) (10μM**) | 310 | | Float | % | |||
| 621 | Outcome(JAK2(Kin.Dom.2)) | 311 | Janus kinase 2 | | Outcome | |||
| 622 | %Inhibition(JAK2(Kin.Dom.2)) (10μM**) | 311 | | Float | % | |||
| 623 | Outcome(JAK3(Kin.Dom.2)) | 312 | Janus kinase 3 | | Outcome | |||
| 624 | %Inhibition(JAK3(Kin.Dom.2)) (10μM**) | 312 | | Float | % | |||
| 625 | Outcome(KIT(V559D,T670I)) | 313 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | | Outcome | |||
| 626 | %Inhibition(KIT(V559D,T670I)) (10μM**) | 313 | | Float | % | |||
| 627 | Outcome(KIT(V559D,V654A)) | 314 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | | Outcome | |||
| 628 | %Inhibition(KIT(V559D,V654A)) (10μM**) | 314 | | Float | % | |||
| 629 | Outcome(MAP3K3) | 315 | mitogen-activated protein kinase kinase kinase 3 | | Outcome | |||
| 630 | %Inhibition(MAP3K3) (10μM**) | 315 | | Float | % | |||
| 631 | Outcome(MAP4K2) | 316 | mitogen-activated protein kinase kinase kinase kinase 2 | | Outcome | |||
| 632 | %Inhibition(MAP4K2) (10μM**) | 316 | | Float | % | |||
| 633 | Outcome(MAPKAPK5) | 317 | mitogen-activated protein kinase-activated protein kinase 5 | | Outcome | |||
| 634 | %Inhibition(MAPKAPK5) (10μM**) | 317 | | Float | % | |||
| 635 | Outcome(MINK) | 318 | misshapen-like kinase 1 (zebrafish) | | Outcome | |||
| 636 | %Inhibition(MINK) (10μM**) | 318 | | Float | % | |||
| 637 | Outcome(MST1R) | 319 | macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | | Outcome | |||
| 638 | %Inhibition(MST1R) (10μM**) | 319 | | Float | % | |||
| 639 | Outcome(p38-delta) | 320 | mitogen-activated protein kinase 13 | | Outcome | |||
| 640 | %Inhibition(p38-delta) (10μM**) | 320 | | Float | % | |||
| 641 | Outcome(PFTAIRE2) | 321 | PFTAIRE protein kinase 2 | | Outcome | |||
| 642 | %Inhibition(PFTAIRE2) (10μM**) | 321 | | Float | % | |||
| 643 | Outcome(PIK3C2B) | 322 | phosphoinositide-3-kinase, class 2, beta polypeptide | | Outcome | |||
| 644 | %Inhibition(PIK3C2B) (10μM**) | 322 | | Float | % | |||
| 645 | Outcome(PIK3CB) | 323 | phosphoinositide-3-kinase, catalytic, beta polypeptide | | Outcome | |||
| 646 | %Inhibition(PIK3CB) (10μM**) | 323 | | Float | % | |||
| 647 | Outcome(PIK3CD) | 324 | phosphoinositide-3-kinase, catalytic, delta polypeptide | | Outcome | |||
| 648 | %Inhibition(PIK3CD) (10μM**) | 324 | | Float | % | |||
| 649 | Outcome(PIK3CG) | 325 | phosphoinositide-3-kinase, catalytic, gamma polypeptide | | Outcome | |||
| 650 | %Inhibition(PIK3CG) (10μM**) | 325 | | Float | % | |||
| 651 | Outcome(RET(V804L)) | 326 | ret proto-oncogene | | Outcome | |||
| 652 | %Inhibition(RET(V804L)) (10μM**) | 326 | | Float | % | |||
| 653 | Outcome(RET(V804M)) | 327 | ret proto-oncogene | | Outcome | |||
| 654 | %Inhibition(RET(V804M)) (10μM**) | 327 | | Float | % | |||
| 655 | Outcome(RIOK2) | 328 | RIO kinase 2 (yeast) | | Outcome | |||
| 656 | %Inhibition(RIOK2) (10μM**) | 328 | | Float | % | |||
| 657 | Outcome(RIPK4) | 329 | receptor-interacting serine-threonine kinase 4 | | Outcome | |||
| 658 | %Inhibition(RIPK4) (10μM**) | 329 | | Float | % | |||
| 659 | Outcome(ROCK2) | 330 | Rho-associated, coiled-coil containing protein kinase 2 | | Outcome | |||
| 660 | %Inhibition(ROCK2) (10μM**) | 330 | | Float | % | |||
| 661 | Outcome(RPS6KA1(Kin.Dom.1)) | 331 | ribosomal protein S6 kinase, 90kDa, polypeptide 1 | | Outcome | |||
| 662 | %Inhibition(RPS6KA1(Kin.Dom.1)) (10μM**) | 331 | | Float | % | |||
| 663 | Outcome(RPS6KA1(Kin.Dom.2)) | 332 | ribosomal protein S6 kinase, 90kDa, polypeptide 1 | | Outcome | |||
| 664 | %Inhibition(RPS6KA1(Kin.Dom.2)) (10μM**) | 332 | | Float | % | |||
| 665 | Outcome(RPS6KA2(Kin.Dom.1)) | 333 | ribosomal protein S6 kinase, 90kDa, polypeptide 2 | | Outcome | |||
| 666 | %Inhibition(RPS6KA2(Kin.Dom.1)) (10μM**) | 333 | | Float | % | |||
| 667 | Outcome(RPS6KA2(Kin.Dom.2)) | 334 | ribosomal protein S6 kinase, 90kDa, polypeptide 2 | | Outcome | |||
| 668 | %Inhibition(RPS6KA2(Kin.Dom.2)) (10μM**) | 334 | | Float | % | |||
| 669 | Outcome(RPS6KA3(Kin.Dom.1)) | 335 | ribosomal protein S6 kinase, 90kDa, polypeptide 3 | | Outcome | |||
| 670 | %Inhibition(RPS6KA3(Kin.Dom.1)) (10μM**) | 335 | | Float | % | |||
| 671 | Outcome(RPS6KA4(Kin.Dom.1)) | 336 | ribosomal protein S6 kinase, 90kDa, polypeptide 4 | | Outcome | |||
| 672 | %Inhibition(RPS6KA4(Kin.Dom.1)) (10μM**) | 336 | | Float | % | |||
| 673 | Outcome(RPS6KA4(Kin.Dom.2)) | 337 | ribosomal protein S6 kinase, 90kDa, polypeptide 4 | | Outcome | |||
| 674 | %Inhibition(RPS6KA4(Kin.Dom.2)) (10μM**) | 337 | | Float | % | |||
| 675 | Outcome(RPS6KA5(Kin.Dom.1)) | 338 | ribosomal protein S6 kinase, 90kDa, polypeptide 5 | | Outcome | |||
| 676 | %Inhibition(RPS6KA5(Kin.Dom.1)) (10μM**) | 338 | | Float | % | |||
| 677 | Outcome(RPS6KA5(Kin.Dom.2)) | 339 | ribosomal protein S6 kinase, 90kDa, polypeptide 5 | | Outcome | |||
| 678 | %Inhibition(RPS6KA5(Kin.Dom.2)) (10μM**) | 339 | | Float | % | |||
| 679 | Outcome(RPS6KA6(Kin.Dom.1)) | 340 | ribosomal protein S6 kinase, 90kDa, polypeptide 6 | | Outcome | |||
| 680 | %Inhibition(RPS6KA6(Kin.Dom.1)) (10μM**) | 340 | | Float | % | |||
| 681 | Outcome(RPS6KA6(Kin.Dom.2)) | 341 | ribosomal protein S6 kinase, 90kDa, polypeptide 6 | | Outcome | |||
| 682 | %Inhibition(RPS6KA6(Kin.Dom.2)) (10μM**) | 341 | | Float | % | |||
| 683 | Outcome(SgK110) | 342 | similar to Putative uncharacterized serine/threonine-protein kinase SgK110 | | Outcome | |||
| 684 | %Inhibition(SgK110) (10μM**) | 342 | | Float | % | |||
| 685 | Outcome(SRPK3) | 343 | SFRS protein kinase 3 | | Outcome | |||
| 686 | %Inhibition(SRPK3) (10μM**) | 343 | | Float | % | |||
| 687 | Outcome(STK35) | 344 | serine/threonine kinase 35 | | Outcome | |||
| 688 | %Inhibition(STK35) (10μM**) | 344 | | Float | % | |||
| 689 | Outcome(TAK1) | 345 | mitogen-activated protein kinase kinase kinase 7 | | Outcome | |||
| 690 | %Inhibition(TAK1) (10μM**) | 345 | | Float | % | |||
| 691 | Outcome(TAOK1) | 346 | TAO kinase 1 | | Outcome | |||
| 692 | %Inhibition(TAOK1) (10μM**) | 346 | | Float | % | |||
| 693 | Outcome(TAOK3) | 347 | TAO kinase 3 | | Outcome | |||
| 694 | %Inhibition(TAOK3) (10μM**) | 347 | | Float | % | |||
| 695 | Outcome(TYK2(Kin.Dom.1)) | 348 | tyrosine kinase 2 | | Outcome | |||
| 696 | %Inhibition(TYK2(Kin.Dom.1)) (10μM**) | 348 | | Float | % | |||
| 697 | Outcome(TYK2(Kin.Dom.2)) | 349 | tyrosine kinase 2 | | Outcome | |||
| 698 | %Inhibition(TYK2(Kin.Dom.2)) (10μM**) | 349 | | Float | % | |||
| 699 | Outcome(ULK1) | 350 | unc-51-like kinase 1 (C. elegans) | | Outcome | |||
| 700 | %Inhibition(ULK1) (10μM**) | 350 | | Float | % | |||
| 701 | Outcome(ULK2) | 351 | unc-51-like kinase 2 (C. elegans) | | Outcome | |||
| 702 | %Inhibition(ULK2) (10μM**) | 351 | | Float | % | |||
| 703 | Outcome(ULK3) | 352 | unc-51-like kinase 3 (C. elegans) | | Outcome | |||
| 704 | %Inhibition(ULK3) (10μM**) | 352 | | Float | % | |||
| 705 | Outcome(WEE2) | 353 | WEE1 homolog 2 (S. pombe) | | Outcome | |||
| 706 | %Inhibition(WEE2) (10μM**) | 353 | | Float | % |
** Test Concentration. § Panel component ID.
Additional Information
Grant Number: X01 MH077633-01
Classification
PageFrom: